<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        25-249-16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LEZODEX 2.5 mg tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LETROZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        165.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L02BG04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>LEZODEX for use as adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer and as extended adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women who have received approximately 5 years of prior standard adjuvant tamoxifen therapy, has been approved with conditions, pending the results of studies to verify its clinical benefit.</p><p>&nbsp;</p><p><u><strong>a- What it does:</strong></u></p><p>Estrogen is a normally occurring female sex hormone that stimulates normal breast tissue and the growth of some types of breast cancer. LEZODEX is an aromatase inhibitor which acts by binding to aromatase, a substance needed to make estrogen. As a result, the production of estrogen and the growth of breast cancer are reduced.</p><p>&nbsp;</p><p><u><strong>b- What is adjuvant therapy:</strong></u></p><p>Adjuvant therapy in breast cancer refers to treatment following breast surgery (the primary or initial treatment) in order to reduce the risk of recurrence. The purpose of adjuvant therapy with LEZODEX is to treat hormone receptor-positive early breast cancer, after surgery, in postmenopausal women to reduce the risk of recurrence.</p><p>&nbsp;</p><p><u><strong>c- What is extended adjuvant therapy?</strong></u></p><p>The purpose of extended adjuvant therapy with LEZODEX is to treat hormone receptor- positive early breast cancer in postmenopausal women who have received approximately 5 years of prior standard adjuvant tamoxifen therapy in order to prevent recurrence. Treating breast cancer with LEZODEX beyond the standard 5 years of hormone therapy is called &ldquo;extended adjuvant therapy&rdquo;.</p><p>&nbsp;</p><p><u><strong>d- What the medication is used for</strong></u></p><p>&bull; The adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer;<br />&bull; The extended adjuvant treatment of hormone receptor positive early breast cancer in postmenopausal women who have received approximately 5 years of prior standard adjuvant tamoxifen therapy.<br />&bull; The first-line therapy in postmenopausal women with advanced breast cancer; and<br />&bull; The hormonal treatment of advanced metastatic breast cancer in women with natural or artificially-induced postmenopausal status, who have disease progression following antiestrogen therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u><strong>a- Do not take LEZODEX:</strong></u></p><p>&bull; for children and adolescents under 18 years of age<br />&bull; if you have ever had an unusual or allergic reaction to LEZODEX or any other ingredient in LEZODEX;<br />&bull; if you still have menstrual periods;<br />&bull; if you are pregnant or breast-feeding, as LEZODEX may harm your baby.</p><p>&nbsp;</p><p><u><strong>b- Warnings and precautions:</strong></u></p><p>LEZODEX should be used under the supervision of a doctor experienced in the use of anti-cancer drugs.</p><p>LEZODEX reduces blood estrogen levels which may cause a reduction in bone mineral density and a potential increase in bone loss (osteoporosis) and/or bone fractures.</p><p>The use of aromatase inhibitors, including LEZODEX, may increase the risk of cardiovascular events compared to tamoxifen, such as heart attacks and stroke. Women at risk of heart disease should be carefully monitored by their doctor.</p><p>&nbsp;</p><p><u><strong>c- Pregnancy and breast-feeding:</strong></u></p><p>You should not use LEZODEX if you may become pregnant, are pregnant and/or breastfeeding. There is a potential risk of harm to you and the fetus, including risk of fetal malformations. &nbsp;If you have the potential to become pregnant (this includes women who are perimenopausal or who recently became postmenopausal), you should discuss with your doctor about the need for effective contraception.</p><p>If there is exposure to LEZODEX during pregnancy, you should contact your doctor immediately to discuss the potential of harm to your fetus and potential risk for loss of the pregnancy.</p><p>&nbsp;</p><p><strong><u>d- Take special care:</u></strong></p><p>Before you start taking this medicine, tell your doctor if you:</p><p>&bull; have a serious kidney or serious liver disease;<br />&bull; are taking hormone replacement therapy;<br />&bull; are taking other medication to treat your cancer;<br />&bull; have a personal or family history of osteoporosis or have ever been diagnosed with low bone density or have a recent history of fractures (in order for your doctor to assess your bone health on a regular basis).<br />&bull; have a personal or family history of high blood cholesterol or lipid levels. LEZODEX may increase lipid levels.<br />&bull; have or have had cardiovascular or heart disease including any of the following: heart attack, stroke or uncontrolled blood pressure. LEZODEX may increase the risk of cardiovascular or heart diseases.<br />&bull; have an intolerance to milk sugar (lactose);</p><p>&nbsp;</p><p><strong><u>e- Driving and using machines:</u></strong></p><p>LEZODEX tablets are unlikely to affect your ability to drive a car or to use machinery. However, some patients may occasionally feel tired, dizzy, sleepy or experience visual disorders. If this happens, you should not drive or operate any tools or machinery until you feel normal again.</p><p>&nbsp;</p><p><u><strong>f- Interactions with this medication</strong></u></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other prescription or over-the-counter medicines, vitamins or natural health products during your treatment with LEZODEX.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u><strong>a- How to take LEZODEX:</strong></u></p><p>The usual dosage is one tablet of LEZODEX to be taken once daily. The tablet should be swallowed whole with a small glass of water. You can take LEZODEX with or without food. It is best to take LEZODEX at about the same time every day.</p><p>&nbsp;</p><p><u><strong>b- If you take more LEZODEX than should:</strong></u></p><p>If over dosage is known or suspected, contact your doctor, go to the nearest emergency room, or contact the nearest poison control center for advice immediately. Show the pack of tablets. Medical treatment may be necessary.</p><p>&nbsp;</p><p><u><strong>c- If you forget to take LEZODEX:</strong></u></p><p>If you forget to take a dose of LEZODEX, don&rsquo;t worry; take the missed dose as soon as you remember. &nbsp;However, if it is almost time for the next dose, skip the missed dose and go back to your regular dosage schedule. &nbsp;Do not take a double dose to make up for the one that you missed.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, LEZODEX can have some side effects. Most side effects that have been observed were mild to moderate. Check with your doctor if the unwanted effects do not go away during treatment or become bothersome.<br />Some side effects, such as hot flushes, hair loss or vaginal bleeding may be due to the lack of estrogen in your body.</p><p><strong>Very common side effects (they affect more than 10 in every 100 patients):</strong><br />&bull; hot flushes<br />&bull; night sweat<br />&bull; pain in bones and joints</p><p>&nbsp;</p><p><strong>Common side effects (they affect between 1 to 10 in every 100 patients):</strong><br />&bull; headache&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; rash<br />&bull; dizziness&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; generally feeling unwell<br />&bull; gastrointestinal disorders (such as, nausea, vomiting, indigestion, constipation, diarrhea)<br />&bull; increase in or loss of appetite<br />&bull; increased blood sugar (hyperglycemia)<br />&bull; urinary incontinence&nbsp;&nbsp; &nbsp;&bull; pain in muscles<br />&bull; bone loss&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; bone fractures<br />&bull; depression&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; weight increase<br />&bull; memory problems&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; anxiety<br />&bull; insomnia&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; hair loss<br />&bull; fatigue&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; increased sweating<br />&bull; high level of cholesterol (hypercholesterolemia).</p><p>&nbsp;</p><p><strong>Uncommon side effects (they affect between 1 to 10 in every 1000 patients):</strong><br />&bull; nervous disorders (such as nervousness, irritability, drowsiness)<br />&bull; reduced sense of touch (dysaesthesia)<br />&bull; eye irritation&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; palpitations, rapid heart rate<br />&bull; raised blood pressure (hypertension)<br />&bull; dry skin, itchy rash (urticaria), rapid swelling of face, lips, tongue, throat (angioedema)<br />&bull; severe allergic reaction (anaphylactic reaction)<br />&bull; vaginal disorders (such as bleeding, discharge or dryness)<br />&bull; abdominal pain&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; joint stiffness (arthritis)<br />&bull; breast pain&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; fever<br />&bull; thirst, taste disorder, dry mouth<br />&bull; dryness of mucous membranes<br />&bull; weight decrease&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; cough<br />&bull; urinary tract infection, increased frequency of urination<br />&bull; abnormal liver function test results (blood (blood test disorders).</p><p>If you notice any other side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p><strong>SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM</strong></p></td></tr><tr><td style="width:499px" rowspan="2" colspan="2"><p><strong>Symptom/Effect</strong></p></td><td style="vertical-align:top; width:143px" colspan="2"><p><strong>Talk with your doctor or pharmacist</strong></p></td><td style="vertical-align:top; width:138px" rowspan="2"><p><strong>Stop taking drug and call your doctor or pharmacist</strong></p></td></tr><tr><td style="vertical-align:top; width:62px"><p><strong>Only if severe</strong></p><p>&nbsp;</p></td><td style="vertical-align:top; width:82px"><p><strong>In all cases</strong></p></td></tr><tr><td style="width:79px" rowspan="3" colspan="1"><p><strong>Common</strong></p></td><td style="width:419px"><p>Pain in the muscles, bones and joints;</p></td><td style="width:62px"><p>✔</p></td><td style="width:82px"><p>&nbsp;</p></td><td style="vertical-align:top; width:138px"><p>&nbsp;</p></td></tr><tr><td style="width:419px"><p>Joint stiffness;</p></td><td style="width:62px"><p>✔</p></td><td style="width:82px"><p>&nbsp;</p></td><td style="vertical-align:top; width:138px"><p>&nbsp;</p></td></tr><tr><td style="width:419px"><p>Persistent sad mood (i.e. depression)</p></td><td style="width:62px"><p>&nbsp;</p></td><td style="width:82px"><p>✔</p></td><td style="vertical-align:top; width:138px"><p>&nbsp;</p></td></tr><tr><td style="text-align:center; width:79px" rowspan="2" colspan="1"><p><strong>Uncommon</strong></p></td><td style="width:419px"><p>Tightness or feeling of heaviness in the chest or pain radiating from your chest&nbsp;to your arms or shoulders, neck, teeth or jaw, abdomen or back (signs of angina pectoris or heart attack);</p></td><td style="width:62px"><p>&nbsp;</p></td><td style="width:82px"><p>✔</p></td><td style="vertical-align:middle; width:138px"><p>✔</p></td></tr><tr><td style="vertical-align:middle; width:419px"><p>Numbness or weakness in arm or leg or any part of the&nbsp;body, loss of coordination, vision changes, sudden headache,&nbsp;nausea, loss of coordination, difficulty in speaking or&nbsp;breathing (signs of brain disease e.g. stroke)</p></td><td style="vertical-align:middle; width:62px"><p>&nbsp;</p></td><td style="vertical-align:middle; width:82px"><p>✔</p></td><td style="vertical-align:middle; width:138px"><p>✔</p></td></tr><tr><td style="text-align:center; vertical-align:middle; width:79px" colspan="1"><p>&nbsp;</p></td><td style="vertical-align:middle; width:419px"><p>Swelling and redness along a vein which is extremely&nbsp;tender and possibly painful when touched (signs of inflammation of a vein due to a blood clot, e.g. thrombophlebitis),</p></td><td style="vertical-align:middle; width:62px"><p>&nbsp;</p></td><td style="vertical-align:middle; width:82px"><p>✔</p></td><td style="vertical-align:middle; width:138px"><p>✔</p></td></tr><tr><td style="text-align:center; vertical-align:middle; width:79px" colspan="1"><p>&nbsp;</p></td><td style="vertical-align:middle; width:419px"><p>Difficulty breathing, chest pain, fainting rapid heart rate,&nbsp;bluish skin discoloration (signs of blood clot formation in the&nbsp;lung such as pulmonary embolism),</p></td><td style="vertical-align:middle; width:62px"><p>&nbsp;</p></td><td style="vertical-align:middle; width:82px"><p>✔</p></td><td style="vertical-align:middle; width:138px"><p>✔</p></td></tr><tr><td style="text-align:center; vertical-align:middle; width:79px" colspan="1"><p>&nbsp;</p></td><td style="vertical-align:middle; width:419px"><p>Swelling of arms, hands, feet, ankles or other parts of the body (signs of oedema),</p></td><td style="vertical-align:middle; width:62px"><p>&nbsp;</p></td><td style="vertical-align:middle; width:82px"><p>✔</p></td><td style="vertical-align:middle; width:138px"><p>✔</p></td></tr><tr><td style="text-align:center; vertical-align:middle; width:79px" colspan="1"><p>&nbsp;</p></td><td style="vertical-align:middle; width:419px"><p>Severe fever, chills or mouth ulcers due to infections (signs&nbsp;of low level of white blood cells)</p></td><td style="vertical-align:middle; width:62px"><p>&nbsp;</p></td><td style="vertical-align:middle; width:82px"><p>✔</p></td><td style="vertical-align:middle; width:138px"><p>✔</p></td></tr><tr><td style="text-align:center; vertical-align:middle; width:79px" colspan="1"><p>&nbsp;</p></td><td style="vertical-align:middle; width:419px"><p>Blurred vision (sign of cataract)</p></td><td style="vertical-align:middle; width:62px"><p>&nbsp;</p></td><td style="vertical-align:middle; width:82px"><p>✔</p></td><td style="vertical-align:middle; width:138px"><p>✔</p></td></tr></tbody></table><p>This is not a complete list of side effects. &nbsp;For any unexpected effects while taking LEZODEX, contact your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep this medicine out of the reach and sight of children and pets.<br />&bull; Store your tablets in a dry place below 30&deg;C.&nbsp;<br />&bull; Avoid places where the temperature may rise above 30&deg;C.&nbsp;<br />&bull; Protect from heat and moisture.<br />&bull; Expiry date: Do not take LEZODEX after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of the month. Remember to take any unused medication back to your pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u><strong>a- What the medicinal ingredient:</strong></u><br />&bull; The active substance is Letrozole.<br />&bull; The other ingredients are cellulose compounds (hydroxypropyl cellulose microcrystalline cellulose and hydroxypropyl methylcellulose), iron oxide yellow, lactose, magnesium stearate, polyethylene glycol, sodium starch glycolate and titanium dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                LEZODEX (letrozole) 2.5 mg Tablets
LEZODEX is supplied as film-coated tablets. The film-coated tablets are dark yellow and round biconvex. They are engraved “APO” on one side, “LET” over “2.5” on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Last revised 03/2016 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يُستخدم ليزوديكس كعلاج مساعد للنساء في مرحلة ما بعد انقطاع الطمث واللاتي أُصبن بسرطان الثدي المبكر بسبب الهرمونات، ويُستخدم ليزوديكس كعلاج مساعد ممتد لسرطان الثدي المبكر بسبب الهرمونات في النساء في مرحلة ما بعد انقطاع الطمث اللاتي تلقين علاجًا مساعدًا معياريًا سابقًا بعقار التاموكسفين على ما يقرب من 5 سنوات، وقد تمت الموافقة على هذا الدواء في هذه الحالات، وفي انتظار نتائج الدراسات للتحقق من فائدته الإكلينيكية. &nbsp;لمزيد من المعلومات، يُنصح المرضى بالاتصال بالأطباء المعالجين لهم.</p><p>&nbsp;</p><p><u><strong>أ- كيفية عمل هذا الدواء:</strong></u></p><p>الاستروجين عبارة عن هرمون جنسي أنثوي يُخلق طبيعيًا في الجسم ويحفز نمو أنسجة الثدي الطبيعية ونمو بعض أنواع سرطان الثدي. الدواء ليزوديكس عبارة عن مثبط إنزيم أروماتيز يعمل عن طريق الارتباط بإنزيم أروماتيز، وهو مادة ضرورية لتكوين الاستروجين. ومن ثمَّ ينخفض إنتاج الاستروجين ونمو سرطان الثدي.</p><p>&nbsp;</p><p><u><strong>ب- ما المقصود بالعلاج المساعد:</strong></u></p><p>يشير مصطلح العلاج المساعد في سرطان الثدي إلى العلاج بعد جراحة الثدي (العلاج الأساسي أو الأولي) من أجل خفض احتمال عودة المرض. والهدف من العلاج المساعد باستخدام ليزوديكس هو علاج سرطان الثدي الناتج عن الهرمونات في السيدات في مرحلة ما بعد انقطاع الطمث وبعد خضوعهن للجراحة، وذلك بهدف تقليل احتمال عودة المرض.</p><p>&nbsp;</p><p><u><strong>ج- ما المقصود بالعلاج المساعد الممتد:</strong></u></p><p>الهدف من العلاج المساعد باستخدام ليزوديكس هو علاج سرطان الثدي الناتج عن الهرمونات في السيدات في مرحلة ما بعد انقطاع الطمث اللاتي تلقين علاجًا مساعدًا معياريًا سابقًا بعقار التاموكسفين على ما يقرب من 5 سنوات لمنع عودة المرض. &nbsp;ويُطلق على علاج سرطان الثدي باستخدام مادة ليزوديكس بعد فترة العلاج المعياري بالهرمونات لمدة 5 سنوات - يُطلق عليه &quot;العلاج المساعد الممتد&quot;.</p><p>&nbsp;</p><p><u><strong>د- في ماذا يستعمل هذا الدواء:</strong></u></p><ul><li>للعلاج المساعد في السيدات في مرحلة ما بعد انقطاع الطمث المصابات بسرطان الثدي المبكر بسبب الهرمونات، &nbsp;</li><li>علاج مساعد ممتد لسرطان الثدي المبكر بسبب الهرمونات في النساء في مرحلة ما بعد انقطاع الطمث اللاتي تلقين علاجًا مساعدًا معياريًا سابقًا بعقار التاموكسفين على ما يقرب من 5 سنوات. &nbsp;</li><li>علاج أولي للسيدات في مرحلة ما بعد انقطاع الطمث المصابات بسرطان الثدي المتقدم، و &nbsp;&nbsp;</li><li>العلاج الهرموني لسرطان الثدي الانتقالي المتقدم في السيدات في حالة انقطاع الطمث الطبيعية أو المستحثة صناعيًا، واللاتي تطور عندهن المرض عقب العلاج المضاد للاستروجين.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><u><strong>أ- لا تستخدم ليزوديكس:</strong></u></p><ul><li>للأطفال والمراهقين تحت 18 سنة،</li><li>عند حدوث رد فعل تحسسي لمادة ليزوديكس أو أي مكون آخر في الدواء ليزوديكس، &nbsp;</li><li>عند حدوث دورة الطمث، &nbsp;</li><li>عند الحمل أو الرضاعة الطبيعية، لأن الدواء ليزوديكس قد يضر الطفل.</li></ul><p>&nbsp;</p><p><u><strong>ب- التحذيرات والاحتياطات:</strong></u></p><p>ينبغي استخدام الدواء ليزوديكس تحت إشراف طبيب خبير في استخدام الأدوية المضادة للسرطان. يعمل الدواء ليزوديكس على خفض مستويات الاستروجين في الدم مما قد يسبب انخفاضًا في كثافة المعادن في العظام واحتمال زيادة فقدان العظام (هشاشة العظام) و/أو كسور العظام.</p><p>قد يؤدي استخدام مثبطات إنزيم أروماتيز - بما في ذلك ليزوديكس - إلى زيادة احتمال حدوث الحالات الوعائية القلبية - مقارنة بالدواء تاموكسيفين - مثل النوبات القلبية والسكتة. ينبغي إخضاع السيدات اللاتي يُحتمل إصابتهن بمرض قلبي لإشراف الطبيب. &nbsp;&nbsp;</p><p>&nbsp;</p><p><u><strong>ت- الحمل والرضاعة:</strong></u></p><p>ينبغي عدم استخدام ليزوديكس إذا كان هناك احتمال حدوث حمل أو إذا كان هناك حمل بالفعل و/أو في حالة الرضاعة الطبيعية. &nbsp;هناك احتمال لحدوث ضرر على المريضة والجنين بما في ذلك احتمال حدوث تشوهات خلقية للجنين. &nbsp;إذا كان هناك احتمال حدوث حمل (يشمل هذا السيدات في مرحلة ما قبل انقطاع الطمث أو حديثات العهد بانقطاع الطمث)، فينبغي مناقشة الأمر مع الطبيب لتحديد وسيلة منع الحمل الفعالة. &nbsp;&nbsp;</p><p>في حالة التعرض للدواء ليزوديكس أثناء الحمل، فينبغي الاتصال بالطبيب على الفور لمناقشة احتمال الضرر الذي قد يتعرض له الجنين واحتمال فقدان الحمل.</p><p>&nbsp;</p><p><u><strong>ث- الاحتياطات عند استعمال:</strong></u></p><p>قبل بدء العلاج بالدواء ليزوديكس، ولتحقيق أفضل نتيجة علاجية ممكنة، يُرجى التأكد من إخبار الطبيب بما يلي:&nbsp;</p><ul><li>إذا كان لديك مرض كلوي أو كبدي خطير،&nbsp;</li><li>إذا كنت تستخدمين علاجًا بالهرمونات البديلة، &nbsp;</li><li>إذا كنت تتناولين أدوية أخرى لعلاج السرطان،</li><li>إذا كان لديك تاريخ مرضي شخصي أو عائلي للإصابة بهشاشة العظام، أو سبق تشخيص حالتك بنقص كثافة العظام أو لديك تاريخ مرضي حديث بحالات كسور عظام (لكي يستطيع الطبيب تقييم صحة عظامك بانتظام).</li><li>إذا كان لديك تاريخ مرضي شخصي أو عائلي بارتفاع مستويات الكولسترول أو الدهون في الدم. قد يؤدي ليزوديكس إلى زيادة مستويات الدهون في الدم.&nbsp;</li><li>إذا كان لديك حاليًا أو سابقًا مرض قلبي أو وعائي قلبي بما في ذلك الحالات التالية: &nbsp;نوبة قلبية، سكتة أو ضغط دم غير خاضع للسيطرة. قد يؤدي ليزوديكس إلى زيادة احتمال الأمراض الوعائية القلبية أو القلبية.</li><li>إذا كان لديك عدم تحمل لسكر اللبن (اللاكتوز)،&nbsp;</li></ul><p>&nbsp;</p><p><u><strong>ج- تأثيره على القيادة واستخدام الآلات:</strong></u></p><p>ليس من المحتمل أن تؤثر أقراص ليزوديكس على القدرة عل قيادة المركبات أو استخدام الآلات. &nbsp; ولكن، أحيانًا قد يشعر بعض المرضى بالتعب أو الدوار أو النعاس أو اضطرابات الرؤية. إذا حدث ذلك، فينبغي تجنب قيادة المركبات أو تشغيل أي آلات أو استخدام أدوات حتى تشعرين بحالتك الطبيعية مرة أخرى.&nbsp;</p><p><br />&nbsp;&nbsp;<br /><u><strong>ح- التفاعلات مع هذا الدواء:</strong></u></p><p>يُرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول حاليًا - أو سابقًا - أي أدوية بوصفة طبية أو بدون وصفة طبية أو فيتامينات أو منتجات طبية طبيعية أثناء العلاج باستخدام ليزوديكس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><u><strong>أ- كيف يستخدم ليزوديكس:</strong></u><br />الجرعة العادية هي تناول قرص واحد من ليزوديكس مرة واحدة يوميًا. ينبغي بلع القرص كاملاً مع كوب من الماء. يمكن تناول ليزوديكس مع الطعام أو بدونه. من الأفضل تناول ليزوديكس في الوقت نفسه كل يوم.</p><p>&nbsp;</p><p><u><strong>ب- الجرعة الزائدة:</strong></u><br />في حالة تناول جرعة زائدة أو الاشتباه في ذلك، اتصل بالطبيب، أو اذهب إلى أقرب مركز طوارئ أو اتصل بأقرب مركز لمكافحة السموم للحصول على الرعاية اللازمة على الفور. &nbsp;ينبغي إظهار عبوة الأقراص التي تتناولها للفريق المعالج. فقد تكون المعالجة الطبية أمرًا ضروريًا.</p><p>&nbsp;</p><p><u><strong>ت- الجرعة الفائتة:</strong></u><br />في حالة نسيان جرعة من ليزوديكس، لا تقلق وتناول الجرعة الفائتة حال تذكرها على الفور. &nbsp;ولكن إذا كان الوقت قد اقترب من موعد الجرعة التالية، فتجاوز الجرعة الفائتة وتناول الجرعة المقررة حسب جدول الجرعات الذي تسير عليه. &nbsp;لا تتناول جرعة مزدوجة لتعويض الجرعة الفائتة.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كل الأدوية، يمكن حدوث آثار جانبية من الدواء ليزوديكس. معظم الآثار الجانبية التي تمت ملاحظتها كانت بسيطة إلى متوسطة. يُرجى استشارة الطبيب حال عدم زوال الآثار غير المرغوب فيها أو تفاقمها أثناء العلاج. &nbsp;&nbsp;</p><p>قد ترجع بعض الآثار الجانبية - مثل الاحمرار مع الحرارة أو سقوط الشعر أو النزيف المهبلي - إلى نقص الاستروجين في الجسم. &nbsp;</p><p>&nbsp;</p><p><strong>الآثار الجانبية الشائعة جدًا (تؤثر في أكثر من 10 مرضى من كل 100 مريض):</strong><br />&bull; احمرار مع حرارة &nbsp;<br />&bull; تعرق ليلي &nbsp;&nbsp;<br />&bull; ألم في العظام والمفاصل&nbsp;</p><p>&nbsp;</p><p><strong>الآثار الجانبية الشائعة (تؤثر في عدد من 1 إلى 10 مرضى من كل 100 مريض):</strong><br />&bull; صداع&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; طفح جلدي &nbsp;<br />&bull; دوار &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; شعور عام بعدم الارتياح &nbsp;<br />&bull; اضطرابات في الجهاز الهضمي (مثل الغثيان، والقيء، وعسر الهضم، والإمساك، والإسهال) &nbsp;<br />&bull; زيادة أو نقص الشهية &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; زيادة سكر الدم (هيبرجليسميا) &nbsp;<br />&bull; سلس البول &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; ألم في العضلات &nbsp;<br />&bull; هشاشة عظام &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; كسور العظام &nbsp;<br />&bull; الاكتئاب &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; زيادة في الوزن &nbsp;&nbsp;<br />&bull; اضطرابات الذاكرة &nbsp; &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; قلق &nbsp;<br />&bull; أرق &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; سقوط الشعر &nbsp;<br />&bull; تعب &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; زيادة العرق &nbsp;<br />&bull; ارتفاع مستوى الكولسترول &nbsp;&nbsp;</p><p>&nbsp;</p><p><strong>الآثار الجانبية غير الشائعة (تؤثر في عدد من 1 إلى 10 مرضى من كل 1000 مريض):</strong><br />&bull; اضطرابات عصبية (مثل العصبية، والانفعال والنعاس) &nbsp;<br />&bull; ضعف الشعور باللمس (قصور الحس)&nbsp;&nbsp; &nbsp;&bull; تهيج العين &nbsp;<br />&bull; خفقان، زيادة سرعة القلب &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; ارتفاع ضغط الدم &nbsp;<br />&bull; جفاف الجلد، طفح جلدي مع حكة (ارتيكاريا)، تورم سريع في الوجه والشفتين واللسان والحلق (وذمة وعائية) &nbsp;<br />&bull; رد فعل تحسسي خطير (رد فعل تأقي)&nbsp;&nbsp; &nbsp;&bull; سعال<br />&bull; اضطرابات مهبلية (مثل النزيف أو الإفرازات أو الجفاف) &nbsp;<br />&bull; تصلب المفاصل (التهاب المفاصل)&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; ألم في البطن &nbsp; &nbsp;<br />&bull; ألم في الثدي &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; حمى &nbsp;<br />&bull; عطش، اضطراب التذوق، جفاف الفم &nbsp;&nbsp;&nbsp; &nbsp;&bull; جفاف الأغشية المخاطية &nbsp;<br />&bull; عدوى الجهاز البولي، زياد مرات التبول&nbsp;&nbsp; &nbsp;&bull; نقص الوزن &nbsp; &nbsp;<br />&bull; نتائج غير طبيعية في فحوص الكبد (اضطرابات فحوص الدم). &nbsp;</p><p>في حالة ملاحظة أي آثار جانبية أخر ى غير المذكورة في هذه النشرة، يُرجى إخبار الطبيب أو الصيدلي</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p style="text-align:center" dir="RTL"><strong>الآثار الجانبية الخطيرة، ومدى تكرار حدوثها وكيفية التعامل معها</strong></p></td></tr><tr><td style="width:261px" rowspan="2" colspan="2"><p style="text-align:center" dir="RTL"><strong>العرض/الآثر</strong></p></td><td style="width:45px" colspan="2"><p dir="RTL"><strong>تحدث إلى الطبيب أو الصيدلي</strong></p></td><td rowspan="2"><p dir="RTL"><strong>توقف عن تناول الدواء واتصل بالطبيب أو الصيدلي</strong></p></td></tr><tr><td style="width:1px"><p dir="RTL"><strong>في الحالات الخطرة فقط</strong></p></td><td><p dir="RTL"><strong>في كل الحالات</strong></p></td></tr><tr><td style="width:58px" rowspan="3" colspan="1"><p dir="RTL"><strong>شائعة</strong></p></td><td style="width:201px"><p>ألم في العضلات والعظام</p><p>والمفاصل،</p></td><td style="width:1px"><p>✔</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="width:201px"><p>تصلب المفاصل</p></td><td style="width:1px"><p>✔</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="width:201px"><p>مزاج حزين بشكل دائم (اكتئاب)</p></td><td style="width:1px"><p>&nbsp;</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td style="width:58px" rowspan="7" colspan="1"><p><strong>غير شائعة</strong></p><p>&nbsp;</p></td><td style="width:201px"><p>ضيق أو إحساس بثقل في الصدر أو ألم ينتشر من الصدر إلى الذراعين أو الكتفين أو العنق أو الأسنان أو الفك أو البطن أو الظهر، (علامات الذبحة الصدرية أو نوبة قلبية)،</p></td><td style="width:1px"><p>&nbsp;</p></td><td><p>✔</p></td><td><p>✔</p></td></tr><tr><td style="width:201px"><p>وخز أو ضعف في الذراع أو الساق أو أي جزء من الجسم، أو فقدان التناسق، أو تغيرات في الرؤية، أو صداع مفاجئ، أو غثيان، أو صعوبة في الكلام أو التنفس (علامات مرض الدماغ مثل السكتة)</p></td><td style="width:1px"><p>&nbsp;</p></td><td><p>✔</p></td><td><p>✔</p></td></tr><tr><td style="width:201px"><p>تورم واحمرار في الوريد مع حساسية مفرطة عند اللمس أو شعور بالألم (علامات التهاب الوريد بسبب جلطة دموية مثل التهاب الوريد الخُثاري)،</p></td><td style="width:1px"><p>&nbsp;</p></td><td><p>✔</p></td><td><p>✔</p></td></tr><tr><td style="width:201px"><p>صعوبة في التنفس، ألم في الصدر، إغماء، سرعة القلب الزائدة، زرقان الجلد (علامات تكون جلطة دموية في الرئة مثل الانصمام الرئوي)،</p></td><td style="width:1px"><p>&nbsp;</p></td><td><p>✔</p></td><td><p>✔</p></td></tr><tr><td style="width:201px"><p>تورم الذراعين أو الكفين أو القدمين أو الكاحلين أو أجزاء أخرى من الجسم (علامات وذمة وعائية)،</p></td><td style="width:1px"><p>&nbsp;</p></td><td><p>✔</p></td><td><p>✔</p></td></tr><tr><td style="width:201px"><p>حمى شديدة، قشعريرة أو تقرحات في الفم بسبب العدوى (علامات انخفاض مستوى كرات الدم البيضاء)،</p></td><td style="width:1px"><p>&nbsp;</p></td><td><p>✔</p></td><td><p>✔</p></td></tr><tr><td style="width:201px"><p>تشوش الرؤية (علامات الساد).</p></td><td style="width:1px"><p>&nbsp;</p></td><td><p>✔</p></td><td><p>✔</p></td></tr></tbody></table><p>وهذه لیست قائمة كاملة بكل الآثار الجانبية. وفي حالة حدوث أي آثار غير متوقعة أثناء تناول الدواء ليزوديكس يرجى الاتصال بالطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>يُحفظ هذا الدواء بعيدًا عن متناول ونظر الأطفال والحيوانات الأليفة. &nbsp;</li><li>ينبغي تخزين الأقراص في مكان جاف في درجة حرارة أقل من 30 درجة مئوية.&nbsp;</li><li>ينبغي تجنب الأماكن التي ترتفع فيها درجات الحرارة فوق 30 درجة مئوية.&nbsp;</li><li>ينبغي حفظ الدواء بعيدًا عن الحرارة والرطوبة. &nbsp;</li><li>تاريخ انتهاء الصلاحية: لا يؤخذ الدواء ليزوديكس بعد تاريخ انتهاء الصلاحية المكتوب على العلبة الكرتون بعد الأحرف EXP. &nbsp;يشير تاريخ الصلاحية إلى آخر يوم في الشهر المكتوب. &nbsp;يُرجى تذكر إرجاع أي أدوية غير مستخدمة إلى الصيدلي.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>المادة الفعالة هي ليتروزول.</strong></p><p>المكونات الاخرى هي مركبات السيلولوز (هيدروكسي بروبيل سيلولوز، سيلولوز دقيق البللورات، هيدروكسي بروبيل ميثيل سيلولوز)، أكسيد حديد أصفر، لاكتوز، ستيرات ماغنيسيوم، بولي ايثيلين جليكول، جليكولات نشا الصوديوم، ثاني أكسيد التيتانيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ليزوديكس (ليتروزول) أقراص 2.5 ملجم<br />&nbsp;<br />يوجد ليزوديكس في شكل أقراص مغلفة بطبقة رقيقة. الأقراص المغلفة بطبقة رقيقة صفراء داكنة ومستديرة محدبة من الجانبين. منقوش على أحد الجانبين الأحرف &quot;APO&quot; وعلى الجانب الآخر منقوش الأحرف &quot;LET&quot; على الرقم &quot;2.5&quot;.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة أبوتكس، في مدينة تورنتو، مقاطعة أونتاريو، M9L 1T9.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة في: 03/2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LEZODEX
Letrozole Tablets 2.5mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LEZODEX 2.5 mg Tablets: Each dark yellow, round, biconvex, film-coated tablet engraved “APO” on one side, “LET” over “2.5” on the other side.contains 2.5 mg of letrozole. Available in blisters of 3x10 tablets and bottles of 100 tablets.

In addition to the active ingredient, letrozole, each tablet also contains the non-medicinal ingredients cellulose compounds (hydroxypropyl cellulose, microcrystalline cellulose and hydroxypropyl methylcellulose), iron oxide yellow, lactose, magnesium stearate, polyethylene glycol, sodium starch glycolate and titanium dioxide..

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2.5mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LEZODEX (letrozole) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.</p><p>Approval is based on superior Disease-Free Survival (DFS) compared to tamoxifen from the overall study population, at a median follow-up of 26 months. However, DFS advantage &nbsp;of letrozole over tamoxifen was not observed in the subset of patients with node-negative disease (see <strong>CLINICAL TRIALS </strong>section).</p><p>LEZODEX (letrozole) is also indicated for the extended adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women who have received approximately 5 years of prior standard adjuvant tamoxifen therapy.</p><p>Although the intended duration of extended adjuvant therapy with letrozole is 5 years, randomized, double-blinded data on efficacy endpoints is limited to a median follow-up of 28 months. After this time, the study was unblinded and patients who had received placebo had the option to switch in a non-randomized fashion to treatment with letrozole. At a median follow-up of 30 months, a non- significant increase in deaths (<em>P</em>=0.749) occurred in the letrozole arm in node-negative patients (HR 1.1 (CI 0.62, 1.96): 24/1298 in the letrozole arm versus 22/1301 in the placebo arm). The clinical evidence collected to date demonstrates a statistically significant increase in disease-free survival, but no overall survival advantage has been consistently demonstrated.</p><p>LEZODEX (letrozole) is indicated as first-line therapy in postmenopausal women with advanced breast cancer.</p><p>LEZODEX (letrozole) is also indicated for the hormonal treatment of advanced/metastatic breast cancer in women with natural or artificially-induced postmenopausal status, who have disease progression following antiestrogen therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Dosing</u></strong><strong><u> </u></strong><strong><u>Considerations</u></strong></p><p><strong>&nbsp;</strong>Insufficient data available to recommend dose adjustment in patients with severe hepatic impairment (see <strong>Patients</strong><strong> with hepatic and/or renal impairment</strong>).</p><p>&nbsp;</p><p><strong><u>Recommended Dose and Dosage Adjustment</u></strong></p><p><strong>Adult</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Elderly</strong><strong> </strong><strong>Patients:</strong><strong> </strong>The recommended dose is one 2.5 mg tablet once daily. No dose adjustment is required for elderly patients.</p><p>In the adjuvant setting, the intended duration of treatment is 5 years, although data are limited to a median follow-up of 26 months.</p><p>In the extended adjuvant setting, treatment with LEZODEX (letrozole) is intended for 5 years, although scientific evidence collected to date covers a median follow-up of 49 months.</p><p>In the first- and second-line advanced breast cancer settings, LEZODEX (letrozole) treatment should continue until further tumour progression is evident.</p><p><strong>Patients</strong><strong> </strong><strong>with hepatic and/or renal impairment: </strong>No dosage adjustment is required for patients with renal impairment (creatinine clearance &ge;10 mL/min) or moderate hepatic impairment. Insufficient data are available to recommend a dose adjustment in breast cancer patients with severe non-metastatic hepatic impairment. Therefore, patients with severe hepatic impairment (Child-Pugh score C) should be kept under close supervision for adverse events (see <strong>WARNINGS</strong><strong> </strong><strong>AND</strong><strong> PRECAUTIONS </strong>section).</p><p>&nbsp;</p><p><strong><u>Missed Dose</u></strong></p><p>The missed dose should be taken as soon as the patient remembers. However, if it is almost time for the next dose, the missed dose should be skipped, and the patient should go back to her regular dosage schedule. Do not double doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Premenopausal endocrine status, pregnancy, lactation (see WARNINGS AND PRECAUTIONS section).

•	Patients who are hypersensitive to letrozole, other aromatase inhibitors, or to any ingredient in the formulation or component of the container. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the product monograph.

•	In  the  absence  of  clinical  experience  with  the  use  of  LEZODEX  in  children  or adolescents (under 18 years of age), LEZODEX should not be used in these patients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p style="text-align:center"><strong>Serious</strong><strong> Warnings and Precautions</strong></p><ul><li>LEZODEX (letrozole) should be administered under supervision of a qualified physician experienced in the use of anti-cancer agents.</li><li>Osteoporosis (see Musculoskeletal section, below).</li></ul></td></tr></tbody></table><p>&nbsp;</p><p><strong><u>General</u></strong></p><p>Clinical trial evidence (median follow-up duration of 26 months in the adjuvant setting, 49 months in the extended adjuvant setting) is insufficient to assess adverse effects associated with long term use of letrozole for five years.</p><p>&nbsp;</p><p><strong>Ability to drive and use machines: </strong>Since fatigue and dizziness have been observed with the use of letrozole, and somnolence has been reported uncommonly, caution is advised when driving or using machines.</p><p>&nbsp;</p><p><strong><u>Cardiovascular Disease</u></strong></p><p>In the adjuvant setting, the use of some aromatase inhibitors, including letrozole, may increase the risk of cardiovascular events compared to tamoxifen. The overall incidence of cardiovascular events in the BIG 1-98 study for letrozole and tamoxifen arms was 9.7 vs. 10.5%, respectively. However, a higher incidence of events was seen for letrozole vs. tamoxifen, including cardiac failure (0.9 vs. 0.4%, respectively), myocardial infarction (0.8 vs. 0.4%, respectively), fatal cardiac events (0.6 vs. 0.3%, respectively) and numerically higher fatal stroke (0.15%, 6 cases vs. 0.03%, 1 case, respectively), and a lower incidence was seen for thromboembolic events (1.4% vs. 3.0%, respectively). Patients with non-malignant systemic diseases (cardiovascular, renal, hepatic, lung embolism etc.) which would prevent prolonged follow-up were ineligible from enrolment in the BIG 1-98 trial (see <strong>Clinical Trial Adverse Drug Reactions </strong>section).</p><p>In the extended adjuvant setting, in a 5-year, phase III trial, after a median follow-up of 28 months, the incidence of cardiovascular events any time after randomization was comparable between treatment arms; 6.8% in the letrozole arm compared to 6.5% in the placebo arm. The most frequent cardiovascular events were: new or worsening angina (1.4% in the letrozole arm vs. 1.0% in the placebo arm), myocardial infarction (0.6% in the letrozole arm vs. 0.7% in the placebo arm), and stroke/transient ischemic attack (0.9% in the letrozole arm vs. 0.9% in the placebo arm). These results were obtained prior to unblinding the study.</p><p>After the study unblinding, patients randomized to the placebo arm were offered to switch to letrozole or discontinue treatment.</p><p>The updated results obtained from this Phase III study after study unblinding showed that after a median follow-up of approximately 49 months, the frequency of cardiovascular events any time after randomization was higher in the letrozole arm than in placebo arm until the switch (11.1% vs. 8.6 %, respectively). The most frequent cardiovascular events included arrhythmia (4.0% in the letrozole arm vs. 3.3% in the placebo arm until switch), new or worsening angina (1.7% on letrozole vs. 1.2% on placebo until switch), and stroke/transient ischemic attack (1.7% on letrozole vs. 1.3% on placebo until the switch).</p><p>At a median follow-up of approximately 49 months, the number of deaths attributed to a cardiovascular cause during treatment or within 30 days of stopping treatment was slightly higher in the placebo arm [16/2577 (0.6%)] than in the letrozole arm [10/2566 (0.4%)], but the difference was not statistically significant. Of the 16 deaths attributed to a cardiovascular cause in the placebo arm, 12 occurred in the group of 1129 patients who did not switch to letrozole after study unblinding, and 4 occurred in the group of 1448 patients who did switch to letrozole. There was a statistically significant higher incidence of fatal stroke in the letrozole arm [5/2566 (0.2%)] than in the placebo arm (0/2577) (P&lt;0.0001)). (See also <strong>Clinical Trial Adverse Drug Reactions </strong>section).</p><p>&nbsp;</p><p><strong><u>Musculoskeletal</u></strong></p><p><strong>Bone Mineral Density: </strong>Letrozole reduces circulating estrogen levels. The use of estrogen lowering agents, including letrozole, may cause a reduction in bone mineral density (BMD) with a possible consequent increased risk of osteoporosis and fracture. Osteoporosis and/or bone fractures have been reported with the use of letrozole (see also <strong>Special Populations Geriatrics </strong>and <strong>Clinical Trial Adverse Drug Reactions </strong>sections). Therefore, monitoring of overall bone health is recommended during treatment with letrozole. Women should have their osteoporosis risk assessed and managed according to local clinical practice and guidelines.</p><p>&nbsp;</p><p>In the 5-year, phase III trial for extended adjuvant therapy, after a median follow-up of 28 months, the incidence of self-reported osteoporosis any time after randomization was higher in patients who received letrozole (6.9%) than in patients who received placebo (5.5%) (<em>P</em>=0.042). The incidence of clinical fractures any time after randomization was slightly higher in patients who received letrozole than who received placebo (5.9% vs. 5.5% respectively; <em>P</em>= 0.548, not statistically significant). Fracture rates any time after randomization in patients with a history of osteoporosis were 10.6% in the letrozole arm compared to 7.3% in the placebo arm; the difference is not statistically significant (<em>P</em>= 0.161). In patients with a previous history of fractures, fracture rates were 12.2% in the letrozole arm compared to 8.7% in the placebo arm; the difference is not statistically significant (<em>P</em>= 0.177). These results were obtained prior to the study unblinding.</p><p>&nbsp;</p><p>After the study unblinding, patients randomized to the placebo arm were offered to switch to letrozole or discontinue treatment.</p><p>&nbsp;</p><p>The updated results obtained from this phase III trial after unblinding showed that at a median follow-up of approximately 49 months, the incidence of osteoporosis, any time after randomization, was higher in the letrozole arm (12.3%) than in the placebo until switch arm (7.4%) and the letrozole after switch arm (3.6%).</p><p>&nbsp;</p><p>Fracture rates any time after randomization in patients with a history of osteoporosis were 17.7% (55/311) in letrozole arm compared to 10.9% (33/304) in placebo until switch arm and 5.6% (9/162) in the letrozole after switch arm. In patients with a previous history of fractures, fracture rates any time after randomization were 18.1% (52/287) in the letrozole arm compared to 12.2% (37/304) in the placebo arm until switch, and 10.2% (17/167) in the letrozole after switch arm.</p><p>&nbsp;</p><p>The interpretation of the updated results is confounded by the fact that after study unblinding, 56% of patients randomized placebo opted to switch to letrozole, resulting in different median exposure to treatment (47 months for letrozole, 28 months for placebo until switch and 20 months for letrozole after switch). (See also <strong>Clinical Trial Adverse Drug Reactions </strong>section). The study is ongoing.</p><p>&nbsp;</p><p><strong><u>Sexual Function/Reproduction</u></strong></p><p><strong>Reproductive</strong><strong> </strong><strong>Toxicology:</strong><strong> </strong>Letrozole was evaluated for maternal toxicity as well as embryotoxic, fetotoxic and teratogenic potential in female rats following oral administration of daily doses of 0.003, 0.01 or 0.03 mg/kg on gestation days 6 through 17. Oral administration of letrozole to pregnant rats resulted in teratogenicity and maternal toxicity at 0.03 mg/kg. Embryotoxicity and fetotoxicity were seen at doses of &ge;0.003 mg/kg and there was an increase in the incidence of fetal malformation among the animals treated. However it is not known whether this was an indirect consequence of the pharmacological activity of letrozole (inhibition of estrogen biosynthesis) or a direct drug effect.</p><p>&nbsp;</p><p><u>Special Populations</u></p><p><strong>Hepatic Impairment: </strong>In a single dose trial with 2.5 mg letrozole in volunteers with hepatic impairment, mean AUC values of the volunteers with moderate hepatic impairment was 37% higher than in normal subjects, but still within the range seen in subjects with normal hepatic function. In a study comparing the pharmacokinetics of letrozole after a single oral dose of 2.5 mg in eight subjects with liver cirrhosis and severe non-metastatic hepatic impairment (Child-Pugh score C) to those in healthy&nbsp; volunteers (N=8),&nbsp; AUC&nbsp; and&nbsp; t&frac12; increased by&nbsp; 95&nbsp; %&nbsp; and&nbsp; 187%, respectively. Breast cancer patients with severe hepatic impairment are thus expected to be exposed to higher levels of letrozole than patients without severe hepatic dysfunction. Long term effects of this increased exposure have not been studied.</p><p>&nbsp;</p><p>These results indicate that no dosage adjustment is necessary for breast cancer patients with mild to moderate hepatic dysfunction. However, since letrozole elimination depends mainly on intrinsic metabolic clearance, caution is recommended. Insufficient data are available to recommend a dose adjustment in breast cancer patients with severe non-metastatic hepatic impairment. Therefore, such patients should be kept under close supervision for adverse events.</p><p>&nbsp;</p><p><strong>Renal</strong><strong> </strong><strong>Impairment</strong>: Pharmacokinetics of a single 2.5 mg letrozole dose were unchanged in a study in postmenopausal women with varying degrees of renal function (24-hour creatinine clearance = 9-116 mL/min.). In a study in 364 patients with advanced breast cancer there was no significant association between letrozole plasma levels and calculated CLcr&nbsp;(range 22.9 - 211.9 mL/min). No dosage adjustment is required in patients with CLcr &ge;10 mL/min. No data are available for patients with CLcr&nbsp;&le;9 mL/min. The potential risks and benefits to such patients should be considered carefully before prescribing letrozole.</p><p>&nbsp;</p><p><strong>Pregnant Women</strong>: Letrozole should not be given to pregnant women (see CONTRAINDICATIONS).</p><p>&nbsp;</p><p><strong>Women of Child-Bearing Potential</strong>: There have been post-market reports of spontaneous abortions and congenital anomalies in infants of mothers who have taken letrozole. Letrozole should not be given to women with premenopausal endocrine status &nbsp;(see <strong>CONTRAINDICATIONS</strong>). Women who are not premenopausal but have the potential to become pregnant, including women who are perimenopausal or who recently became postmenopausal, should use appropriate contraception while being treated with letrozole (see also <strong><u>Sexual</u> <u>Function/Reproduction</u>, Reproductive Toxicology)</strong>.</p><p>&nbsp;</p><p><strong>Nursing Women:&nbsp;&nbsp;</strong>Letrozole should not be administered to nursing mothers (see CONTRAINDICATIONS).</p><p>&nbsp;</p><p><strong>Geriatrics: </strong>There have been no age-related effects observed on the pharmacokinetics of letrozole.</p><p>&nbsp;</p><p>In the adjuvant setting, more than 8000 postmenopausal women were enrolled in the clinical study (see <strong>CLINICAL TRIALS </strong>section). In total, 36% of patients were aged 65 years or older at enrolment, while 12% were 75 or older. Although more adverse events were generally reported in elderly patients irrespective of study treatment allocation, the differences between the two treatment groups were similar to those of younger patients.</p><p>&nbsp;</p><p>In a 5-year, phase III trial for extended adjuvant therapy, after a median follow-up of 28 months, fracture rates recorded any time after randomization in patients 65 years and older were 7.1% (77/1090) in the letrozole arm compared to 7.5 % (77/1033) in the placebo arm; the difference is not statistically significant (P= 0.738). These results were obtained prior to study unblinding.</p><p>&nbsp;</p><p>After the study unblinding, patients randomized to the placebo arm were offered to switch to letrozole or discontinue treatment.</p><p>&nbsp;</p><p>The updated results obtained from this phase III trial after unblinding at a median follow-up of approximately 49 months, showed that the fracture rates any time after randomization in patients 65 years and older were 12.2% (133/1090) in letrozole arm compared to 10.2% (105/1032) in placebo until switch arm and 6.9% (34/495) in letrozole after switch arm.</p><p>&nbsp;</p><p>The interpretation of the updated results is confounded by the fact that after study unblinding, 56% of patients randomized placebo opted to switch to letrozole, resulting in different median exposure to treatment (47 months for letrozole, 28 months for placebo until switch and 20 months for letrozole after switch). (See also <strong>Clinical Trial Adverse Drug Reactions </strong>section). The study is ongoing.</p><p>&nbsp;</p><p><strong><u>Monitoring and Laboratory Tests</u></strong></p><p><strong>Plasma Lipids: </strong>In the adjuvant setting, the use of aromatase inhibitors, including letrozole, may increase lipid levels (see <strong>Clinical Trial Adverse Drug Reactions </strong>section). Women should have their cholesterol levels assessed and managed according to current clinical practice and guidelines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Drug-Drug</u></strong><strong><u> </u></strong><strong><u>Interactions</u></strong></p><p>Clinical trials of interaction with letrozole and cimetidine or warfarin indicate that coadministration does not result in clinically significant drug interactions.</p><p>A review of the clinical trial database indicated no evidence of other clinically relevant interactions with other commonly prescribed drugs.</p><p><em>In vitro</em>, letrozole inhibits the cytochrome P450 isoenzymes 2A6 and moderately 2C19. CYP2A6 does not play a major role in drug metabolism. In <em>in vitro </em>experiments letrozole was not able to substantially inhibit the metabolism of diazepam (a substrate of CYP2C19) at concentrations approximately 100-fold higher than those observed in plasma at steady-state. Thus clinically relevant interactions with CYP2C19 are unlikely to occur. However, caution should be used in the concomitant administration of drugs whose disposition is mainly dependent on these isoenzymes and whose therapeutic index is narrow.</p><p>&nbsp;</p><p><strong>Use with Other Anticancer Agents: </strong>Co-administration of letrozole and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average. The clinical significance of this finding has not been explored in prospective clinical trials.</p><p>There is no clinical experience to date on the use of letrozole in combination with other anticancer agents.</p><p>&nbsp;</p><p><strong><u>Drug-Food Interactions</u></strong></p><p>Food slightly decreases the rate of absorption (median tmax 1 hour fasted vs. 2 hours fed and mean Cmax 129&plusmn;20.3 nmol/L fasted vs. 98.7&plusmn;18.6 nmol/L fed), but the extent of absorption (area under the curve (AUC)) remains unchanged. This minor effect on absorption rate is not considered to be of clinical relevance and therefore letrozole may be taken with or without food.</p><p>&nbsp;</p><p><strong><u>Drug-Laboratory Interactions</u></strong></p><p>No clinically significant changes in the results of clinical laboratory tests have been observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnant Women</strong>: Letrozole should not be given to pregnant women (see CONTRAINDICATIONS).</p><p>&nbsp;</p><p><strong>Women of Child-Bearing Potential</strong>: There have been post-market reports of spontaneous abortions and congenital anomalies in infants of mothers who have taken letrozole. Letrozole should not be given to women with premenopausal endocrine status &nbsp;(see <strong>CONTRAINDICATIONS</strong>). Women who are not premenopausal but have the potential to become pregnant, including women who are perimenopausal or who recently became postmenopausal, should use appropriate contraception while being treated with letrozole (see also <strong><u>Sexual</u> <u>Function/Reproduction</u>, Reproductive Toxicology)</strong>.</p><p>&nbsp;</p><p><strong>Nursing Women:&nbsp;&nbsp;</strong>Letrozole should not be administered to nursing mothers (see CONTRAINDICATIONS).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Ability to drive and use machines: </strong>Since fatigue and dizziness have been observed with the use of letrozole, and somnolence has been reported uncommonly, caution is advised when driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Adverse</u></strong><strong><u> </u></strong><strong><u>Drug</u></strong><strong><u> </u></strong><strong><u>Reactions</u></strong><strong><u> </u></strong><strong><u>Overview</u></strong></p><p><strong>Adverse</strong><strong> </strong><strong>Events</strong><strong> </strong><strong>in</strong><strong> </strong><strong>Adjuvant</strong><strong> Study BIG 1-98</strong></p><p>The Data and Safety Monitoring Committee, after review of the primary analysis results of the BIG 1-98 study, observed a difference in incidence in grade 5 myocardial infarctions (9 vs. 2 in the letrozole and tamoxifen arms, respectively) and recommended that these cardiac events and certain other safety data be reviewed. As a result, a blinded medical review of more than 2000 patients with pre-specified adverse events (cardiovascular events, fractures, arthritis/arthralgia, myalgia, any adverse event leading to discontinuation) or death without a prior cancer event was conducted following the primary analysis of the adjuvant trial BIG 1-98. This medical review resulted in a change in the cause of death for 25 patients, 19 of which were reclassified from a cardiac cause to either &ldquo;sudden death, cause unknown&rdquo; (9 cases in letrozole arm, 7 cases in tamoxifen arm) or to &ldquo;other&rdquo; (3 cases in letrozole arm). Some adverse events (such as arthritis/arthralgia and edema) reported in the primary analysis did not meet the definition of a treatment-emergent adverse event as they were present at baseline and did not worsen in severity during treatment. The BIG 1-98 study is currently ongoing, and the medical review is being conducted on an ongoing basis; the updated efficacy and safety results from the study will be made available at the 5-year median treatment duration. It is important to note that these updated safety data will not be comparable with those of the primary analysis. Extrapolation of the absolute risk of these pre-specified events as a function of time cannot be reasonably established.</p><p>&nbsp;</p><p>Letrozole was generally well tolerated as adjuvant treatment of early breast cancer. In the adjuvant setting (26 months median follow-up) approximately 91% vs. 86% of the patients allocated to letrozole or tamoxifen, respectively<strong>,</strong><strong> </strong>experienced adverse events. Generally, the observed adverse events were mainly mild or moderate in nature, and most were associated with estrogen deprivation. The most frequently reported adverse events in the adjuvant setting were hot flushes (letrozole: 33.7%, tamoxifen: 38.0%), arthralgia/arthritis (letrozole: 21.2%, tamoxifen 13.5%), and night sweats (letrozole: 14.1%, tamoxifen: 16.4%).</p><p>&nbsp;</p><p><strong>Adverse Events in Extended Adjuvant Study MA-17</strong></p><p>Adverse events discussed below were analyzed irrespective of relationship to study treatment.</p><p>Letrozole was generally well tolerated as extended adjuvant treatment in women who &nbsp;have received prior standard adjuvant tamoxifen treatment. In the phase III trial for extended adjuvant therapy, after a median follow-up of 28 months 87.2% vs. 84.5% of the patients on letrozole or placebo experienced adverse events. The most frequent events were: hot flushes (letrozole 49.7% vs. placebo 43.3%), fatigue (lethargy, asthenia, malaise) (letrozole 33.8% vs. placebo 32.2%), arthralgia/arthritis (letrozole 27.7% vs. placebo 22.2%); and sweating (diaphoresis) (24.3% vs. placebo 22.5%).</p><p>After the study unblinding, patients randomized to placebo arm were offered to switch to letrozole. The placebo results beyond 28 months median follow-up are confounded by the fact that 56% of patients randomised placebo opted to switch to letrozole and that dates of onset for general adverse events (based on self-report) were not recorded. In most cases, therefore, it cannot be determined if the adverse events in the placebo group occurred before switch to letrozole or after switch to letrozole. General adverse event data after unblinding of the study should therefore be interpreted with caution.</p><p>In the extended adjuvant study after study unblinding at a median follow-up of approximately 49 months the overall incidence of adverse events reported during study treatment or within 30 days irrespective of causality was 94.2% in letrozole, 91.1% in placebo not switched and 94.1% in placebo patients switched to letrozole. The most frequent adverse events were: hot flushes (60.3% in letrozole vs. 52.6% in placebo not switched), fatigue (lethargy, malaise, asthenia) (45.0% in letrozole vs. 44.8% in placebo not switched), arthralgia/arthritis (37.9% in letrozole vs. 26.8% in placebo not switched), sweating (diaphoresis) (34.0% in letrozole vs. 29.8% in placebo not switched).</p><p>Most frequently reported adverse events from the clinical trials in adjuvant and extended adjuvant are summarized in Tables 1, 2 and 3.</p><p>&nbsp;</p><p><strong>Adverse Events in First-Line and Second-Line Treatment of Advanced Breast Cancer</strong></p><p>Letrozole was generally well tolerated across all studies as first-line and second-line treatment for advanced breast cancer. Approximately one third of patients treated with letrozole can be expected to experience adverse reactions. The most frequently reported adverse reactions in the clinical trials were hot flushes, nausea and fatigue. Many adverse reactions can be attributed to the normal physiological consequences of estrogen deprivation (e.g., hot flushes, alopecia and vaginal bleeding). The adverse drug reactions reported from clinical trials are summarized for first- line and second-line treatment with letrozole.</p><p>&nbsp;</p><p><strong><u>Clinical Trial Adverse Drug Reactions</u></strong></p><p><strong>Adverse</strong><strong> </strong><strong>Events</strong><strong> </strong><strong>in</strong><strong> </strong><strong>Adjuvant</strong><strong> Treatment of Early Breast Cancer in Postmenopausal Women</strong></p><p>The median duration of adjuvant treatment was 24 months and the median duration of follow-up for safety was 26 months for patients receiving letrozole and tamoxifen.</p><p>Certain adverse events were prospectively specified for analysis, based on the known pharmacologic properties and side effect profiles of the two drugs.</p><p>Most adverse events reported (82%) were grade 1 and grade 2 applying the Common Toxicity Criteria Version 2.0. Serious adverse events that were suspected to be related to study treatment were significantly less frequent with letrozole (177 patients, 4.5%) than with tamoxifen (276 patients, 6.9%). Table 1 describes the most frequently reported adverse events irrespective of relationship to study treatment in the adjuvant BIG 1-98 trial (safety population, during treatment or within 30 days of stopping treatment).</p><p>In the adjuvant setting, total cholesterol levels remained stable over 5 years (median 1-3% decrease) in the letrozole arm whereas there was an expected slight decrease (median 10-15% decrease) over time observed in the tamoxifen arm. Hypercholesterolemia recorded at least once as a check-listed adverse event was more frequent in patients treated with letrozole (43%) compared with tamoxifen (19%). &nbsp;Hypercholesterolemia recorded from non-fasting laboratory evaluations was defined as an increase in total serum cholesterol in patients who had baseline values of total serum cholesterol within the normal range, and then subsequently, had an increase in total serum cholesterol of 1.5* ULN at least one time. The incidence of laboratory evaluated hypercholesterolemia was more frequent in patients treated with letrozole (5.6%) compared to tamoxifen (1.3%) (see Table 1) .</p><p>Overall, the incidence of cardiovascular events was similar in the letrozole and tamoxifen arms (9.7 vs. 10.5%, respectively), although more patients receiving letrozole compared to tamoxifen were reported to have cardiac failure (0.9 vs. 0.4%, respectively), myocardial infarction (0.8 vs. 0.4%, respectively), fatal cardiac events (0.6 vs. 0.3%, respectively), and numerically higher fatal stroke (0.15%, 6 cases vs. 0.03%, 1 case, respectively). As expected, thromboembolic events were more frequent in patients on tamoxifen compared to letrozole (3.0 vs. 1.4%), respectively.</p><p>Patients with other non-malignant systemic diseases (cardiovascular, renal, hepatic, lung embolism etc.) which would prevent prolonged follow-up were ineligible from enrolment in the BIG 1-98 trial. Patients with previous DVT (deep vein thrombosis) were only included if medically suitable.</p><p>See <strong>Adverse Events in Extended Adjuvant Therapy </strong>below for data with respect to placebo.</p><p>Letrozole treatment was associated with a significantly higher risk of osteoporosis (2.0 vs. 1.1% with tamoxifen). Bone fractures were significantly higher in the letrozole arm than the tamoxifen arm (5.7 vs. 4.0%, respectively).</p><p>&nbsp;</p><p><strong>Table 1 - Most frequently reported adverse events irrespective of relationship to study drug in the Adjuvant Trial BIG 1-98</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Letrozole</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>N=3975</strong></p></td><td style="vertical-align:top"><p><strong>N=3988</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Preferred</strong><strong> </strong><strong>Term</strong></p></td><td style="vertical-align:top"><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hot flashes/flushes</p></td><td style="vertical-align:top"><p>1338 (33.7)</p></td><td style="vertical-align:top"><p>1515 (38.0)</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia/Arthritis</p></td><td style="vertical-align:top"><p>841 (21.2)</p></td><td style="vertical-align:top"><p>537 (13.5)</p></td></tr><tr><td style="vertical-align:top"><p>Night sweats</p></td><td style="vertical-align:top"><p>561 (14.1)</p></td><td style="vertical-align:top"><p>654 (16.4)</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>378 (9.5)</p></td><td style="vertical-align:top"><p>418 (10.5)</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue (lethargy,malaise,asthenia)</p></td><td style="vertical-align:top"><p>333 (8.4)</p></td><td style="vertical-align:top"><p>345 (8.7)</p></td></tr><tr><td style="vertical-align:top"><p>Edema</p></td><td style="vertical-align:top"><p>286 (7.2)</p></td><td style="vertical-align:top"><p>288 (7.2)</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>256 (6.4)</p></td><td style="vertical-align:top"><p>243 (6.1)</p></td></tr><tr><td style="vertical-align:top"><p>Bone fractures</p></td><td style="vertical-align:top"><p>226 (5.7)</p></td><td style="vertical-align:top"><p>161 (4.0)</p></td></tr><tr><td style="vertical-align:top"><p>Hypercholesterolemia (1,2)</p></td><td style="vertical-align:top"><p>173 (5.6)</p></td><td style="vertical-align:top"><p>40 (1.3)</p></td></tr><tr><td style="vertical-align:top"><p>Vaginal bleeding</p></td><td style="vertical-align:top"><p>177 (4.5)</p></td><td style="vertical-align:top"><p>413 (10.4)</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>144 (3.6)</p></td><td style="vertical-align:top"><p>155 (3.9)</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>143 (3.6)</p></td><td style="vertical-align:top"><p>126 (3.2)</p></td></tr><tr><td style="vertical-align:top"><p>Vaginal irritation</p></td><td style="vertical-align:top"><p>139 (3.5)</p></td><td style="vertical-align:top"><p>122 (3.1)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>109 (2.7)</p></td><td style="vertical-align:top"><p>107 (2.7)</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness/light-headedness</p></td><td style="vertical-align:top"><p>97 (2.4)</p></td><td style="vertical-align:top"><p>112 (2.8)</p></td></tr><tr><td style="vertical-align:top"><p>Osteoporosis</p></td><td style="vertical-align:top"><p>80 (2.0)</p></td><td style="vertical-align:top"><p>44 (1.1)</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>59 (1.5)</p></td><td style="vertical-align:top"><p>95 (2.4)</p></td></tr><tr><td style="vertical-align:top"><p>Cataract</p></td><td style="vertical-align:top"><p>48 (1.2)</p></td><td style="vertical-align:top"><p>39 (1.0)</p></td></tr><tr><td style="vertical-align:top"><p>Breast Pain</p></td><td style="vertical-align:top"><p>40 (1.0)</p></td><td style="vertical-align:top"><p>47 (1.2)</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac failure</p></td><td style="vertical-align:top"><p>36 (0.9)</p></td><td style="vertical-align:top"><p>15 (0.4)</p></td></tr><tr><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>33 (0.8)</p></td><td style="vertical-align:top"><p>31 (0.8)</p></td></tr><tr><td style="vertical-align:top"><p>Myocardial infarction</p></td><td style="vertical-align:top"><p>31 (0.8)</p></td><td style="vertical-align:top"><p>17 (0.4)</p></td></tr><tr><td style="vertical-align:top"><p>Angina pectoris</p></td><td style="vertical-align:top"><p>27 (0.7)</p></td><td style="vertical-align:top"><p>24 (0.6)</p></td></tr><tr><td style="vertical-align:top"><p>Ovarian cyst</p></td><td style="vertical-align:top"><p>17 (0.4)</p></td><td style="vertical-align:top"><p>14 (0.4)</p></td></tr><tr><td style="vertical-align:top"><p>Endometrial proliferation disorders</p></td><td style="vertical-align:top"><p>10 (0.3)</p></td><td style="vertical-align:top"><p>73 (1.8)</p></td></tr><tr><td style="vertical-align:top"><p>Other endometrial disorders</p></td><td style="vertical-align:top"><p>3 (&lt;0.1)</p></td><td style="vertical-align:top"><p>4 (0.1)</p></td></tr></tbody></table><p><strong>&nbsp;(</strong>1) Based on number of patients with normal serum cholesterol levels at baseline and developing at least one value greater than 1.5 times the upper limit of normal in the laboratory, measuring total serum cholesterol. Approximately 90% of the measured values were non-fasting measurements.</p><p>(2) Denominator is number of patients with baseline measurements of total serum cholesterol &ndash; letrozole, n=3105; tamoxifen, n=3129.</p><p>&nbsp;</p><p><strong>Adverse Events in Extended Adjuvant Therapy in Early Breast Cancer, Median Treatment Duration of 24 Months</strong></p><p>Table 2 below describes the adverse events occurring at a frequency of at least 2% in any treatment group in a well-controlled clinical study in which over 5100 postmenopausal patients with receptor-positive or unknown primary breast cancer patients who had remained disease-free after completion of adjuvant treatment with tamoxifen were randomly assigned either letrozole or placebo. The median duration of extended adjuvant treatment was 24 months and the median duration of follow-up for safety was 28 months for patients receiving letrozole and placebo<strong><em>.</em></strong><strong><em> </em></strong>Most adverse events reported were grade 1 or grade 2 based on the Common Toxicity Criteria Version 2.0.</p><p>&nbsp;</p><p><strong>Table 2 - Most frequently reported adverse events irrespective of relationship to study drug (median treatment duration 24 months) in the Extended Adjuvant Trial MA-17</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Letrozole</strong><strong> </strong></p><p><strong>N=</strong><strong> </strong><strong>2563</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong><strong> </strong></p><p><strong>N=</strong><strong> </strong><strong>2573</strong></p><p><strong>n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Any</strong><strong> </strong><strong>adverse</strong><strong> </strong><strong>event</strong></p></td><td style="vertical-align:top"><p>2234 (87.2)</p></td><td style="vertical-align:top"><p>2174 (84.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>90 (3.5)</p></td><td style="vertical-align:top"><p>113 (4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>91 (3.6)</p></td><td style="vertical-align:top"><p>79 (3.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal</strong></p></td><td style="vertical-align:top"><p>725 (28.3)</p></td><td style="vertical-align:top"><p>731 (28.4)</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>290 (11.3)</p></td><td style="vertical-align:top"><p>304 (11.8)</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>221 (8.6)</p></td><td style="vertical-align:top"><p>212 (8.2)</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea (NOS)</p></td><td style="vertical-align:top"><p>128 (5.0)</p></td><td style="vertical-align:top"><p>143 (5.6)</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain (NOS)</p></td><td style="vertical-align:top"><p>74 (2.9)</p></td><td style="vertical-align:top"><p>86 (3.3)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>75 (2.9)</p></td><td style="vertical-align:top"><p>83 (3.2)</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>72 (2.8)</p></td><td style="vertical-align:top"><p>82 (3.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>General</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>1155 (45.1)</p></td><td style="vertical-align:top"><p>1090 (42.4)</p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>862 (33.6)</p></td><td style="vertical-align:top"><p>826 (32.1)</p></td></tr><tr><td style="vertical-align:top"><p>Edema (NOS)</p></td><td style="vertical-align:top"><p>471 (18.4)</p></td><td style="vertical-align:top"><p>416 (16.2)</p></td></tr><tr><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>59 (2.3)</p></td><td style="vertical-align:top"><p>69 (2.7)</p></td></tr><tr><td style="vertical-align:top"><p>Pain (NOS)</p></td><td style="vertical-align:top"><p>56 (2.2)</p></td><td style="vertical-align:top"><p>47 (1.8)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections</strong><strong> and Infestations</strong></p></td><td style="vertical-align:top"><p>166 (6.5)</p></td><td style="vertical-align:top"><p>163 (6.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigation</strong></p></td><td style="vertical-align:top"><p>184 (7.2)</p></td><td style="vertical-align:top"><p>147 (5.7)</p></td></tr><tr><td style="vertical-align:top"><p>Weight increased</p></td><td style="vertical-align:top"><p>55 (2.1)</p></td><td style="vertical-align:top"><p>51 (2.0)</p></td></tr><tr><td style="vertical-align:top"><p>Weight decreased</p></td><td style="vertical-align:top"><p>52 (2.0)</p></td><td style="vertical-align:top"><p>38 (1.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism</strong><strong> and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>551 (21.5)</p></td><td style="vertical-align:top"><p>537 (20.9)</p></td></tr><tr><td style="vertical-align:top"><p>Hypercholesterolaemia</p></td><td style="vertical-align:top"><p>401 (15.6)</p></td><td style="vertical-align:top"><p>398 (15.5)</p></td></tr><tr><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>119 (4.6)</p></td><td style="vertical-align:top"><p>96 (3.7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>978 (38.2)</p></td><td style="vertical-align:top"><p>836 (32.5)</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Letrozole</strong></p><p><strong>N=</strong><strong> </strong><strong>2563</strong><strong> </strong><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N=</strong><strong> </strong><strong>2573</strong><strong> </strong><strong>n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>565 (22.0)</p></td><td style="vertical-align:top"><p>465 (18.1)</p></td></tr><tr><td style="vertical-align:top"><p>Arthritis (NOS)</p></td><td style="vertical-align:top"><p>173 (6.7)</p></td><td style="vertical-align:top"><p>124 (4.8)</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>171 (6.7)</p></td><td style="vertical-align:top"><p>122 (4.7)</p></td></tr><tr><td style="vertical-align:top"><p>Fractures</p></td><td style="vertical-align:top"><p>152 (5.9)</p></td><td style="vertical-align:top"><p>142 (5.5)</p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>129 (5.0)</p></td><td style="vertical-align:top"><p>112 (4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Bone pain</p></td><td style="vertical-align:top"><p>70 (2.7)</p></td><td style="vertical-align:top"><p>81 (3.1)</p></td></tr><tr><td style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>70 (2.7)</p></td><td style="vertical-align:top"><p>62 (2.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Neoplasms</strong><strong> </strong><strong>benign,</strong><strong> </strong><strong>malignant</strong><strong> </strong><strong>and</strong><strong> unspecified</strong></p></td><td style="vertical-align:top"><p>51 (2.0)</p></td><td style="vertical-align:top"><p>48 (1.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous</strong><strong> </strong><strong>system</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>865 (33.7)</p></td><td style="vertical-align:top"><p>819 (31.8)</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>516 (20.1)</p></td><td style="vertical-align:top"><p>508 (19.7)</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>363 (14.2)</p></td><td style="vertical-align:top"><p>342 (13.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>320 (12.5)</p></td><td style="vertical-align:top"><p>276 (10.7)</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>149 (5.8)</p></td><td style="vertical-align:top"><p>120 (4.7)</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>115 (4.5)</p></td><td style="vertical-align:top"><p>104 (4.0)</p></td></tr><tr><td style="vertical-align:top"><p>Anxiety</p></td><td style="vertical-align:top"><p>78 (3.0)</p></td><td style="vertical-align:top"><p>73 (2.8)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>130 (5.1)</p></td><td style="vertical-align:top"><p>100 (3.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>303 (11.8)</p></td><td style="vertical-align:top"><p>357 (13.9)</p></td></tr><tr><td style="vertical-align:top"><p>Vulvovaginal dryness</p></td><td style="vertical-align:top"><p>137 (5.3)</p></td><td style="vertical-align:top"><p>127 (4.9)</p></td></tr><tr><td style="vertical-align:top"><p>Vaginal haemorrhage</p></td><td style="vertical-align:top"><p>123 (4.8)</p></td><td style="vertical-align:top"><p>171 (6.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory</strong><strong> </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>280 (10.9)</p></td><td style="vertical-align:top"><p>261 (10.1)</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>140 (5.5)</p></td><td style="vertical-align:top"><p>137 (5.5)</p></td></tr><tr><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>96 (3.7)</p></td><td style="vertical-align:top"><p>94 (3.7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>830 (32.4)</p></td><td style="vertical-align:top"><p>787 (30.6)</p></td></tr><tr><td style="vertical-align:top"><p>Sweating increased</p></td><td style="vertical-align:top"><p>619 (24.2)</p></td><td style="vertical-align:top"><p>577 (22.4)</p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>112 (4.4)</p></td><td style="vertical-align:top"><p>83 (3.2)</p></td></tr><tr><td style="vertical-align:top"><p>Rash (NOS)</p></td><td style="vertical-align:top"><p>41 (1.6)</p></td><td style="vertical-align:top"><p>53 (2.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>1376 (53.7)</p></td><td style="vertical-align:top"><p>1230 (47.8)</p></td></tr><tr><td style="vertical-align:top"><p>Flushing (1)</p></td><td style="vertical-align:top"><p>1273 (49.7)</p></td><td style="vertical-align:top"><p>1114 (43.3)</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension (NOS)</p></td><td style="vertical-align:top"><p>122 (4.8)</p></td><td style="vertical-align:top"><p>110 (4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Lymphoedema (NOS)</p></td><td style="vertical-align:top"><p>68 (2.7)</p></td><td style="vertical-align:top"><p>79 (3.1)</p></td></tr></tbody></table><p><strong>&nbsp;</strong>(1) Includes terms &ldquo;hot flashes/hot flushes&rdquo;.</p><p>(NOS) : Not Otherwise Specified</p><p>&nbsp;</p><p>The incidence of self-reported osteoporosis from the MA-17 core study was significantly higher in patients who received letrozole 6.9% (176) than in patients who received placebo 5.5% (141) (<em>P</em>=0.042). The incidence of clinical fractures was 5.9% (152) in patients who received letrozole compared to 5.5% (142) in&nbsp; patients who&nbsp; received placebo, the&nbsp; difference is&nbsp; not&nbsp; statistically significant (<em>P</em>=0.548).</p><p>Results (median duration of follow-up was 20 months) from the MA-17 bone sub-study demonstrated that, at 2 years, compared to baseline, patients receiving letrozole had a mean decrease (versus baseline) of 3% versus 0.4% (<em>P</em>=0.048) in placebo for hip bone mineral density. There was no significant difference in terms of lumbar spine bone mineral density.</p><p>The incidence of cardiovascular ischemic events from the MA-17 core study was comparable between patients who received letrozole 6.8% (175) and placebo 6.5% (167) (<em>P</em>=NS).</p><p>Results from the MA-17 lipid study (median follow-up 36 months) did not show significant differences between the letrozole and placebo groups. Subjects did not have a prior history of hyperlipidemia. The study continues to investigate the long term impact of letrozole on lipid levels. As per normal clinical practice and guidelines for post-menopausal women, physicians should continue their routine monitoring of lipid levels on a regular basis.</p><p>&nbsp;</p><p><strong>Adverse Events in Extended Adjuvant Therapy in Early Breast Cancer, Median Treatment Duration of 47 Months and a Median Follow-up of 49 Months</strong></p><p>Adverse events discussed below were analyzed irrespective of relationship to study treatment.</p><p>Table 3 below compares the self-reported adverse events irrespective of drug relationship experienced in the randomized letrozole arm at a median treatment duration of 24 months and 47 months. The table describes the adverse events occurring in the safety population at a cut-off frequency of at least 2%. Most of these adverse events were grade 1 or grade 2 based on Common Toxicity Criteria Version 2.0. The placebo comparison after unblinding is not reliable due to the fact that 56% of patients randomized placebo opted to switch to letrozole and dates of onset for general adverse events (based on self-report) were not recorded. In most cases, therefore, it cannot be determined if the adverse events in the placebo group occurred before switch to letrozole or after switch to letrozole. The safety population after study unblinding consists of 2566 patients in the letrozole arm, 1129 patients in the placebo not switched arm and 1448 patients in the letrozole after switch from placebo arm. The median 24 months of treatment duration versus the median 47 months of treatment duration comparison is presented to indicate the evolution of adverse events in the letrozole arm over time.</p><p>&nbsp;</p><p><strong>Table 3 - Most frequently reported adverse events irrespective of relationship to study drug in the Extended Adjuvant Trial MA-17</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Letrozole&nbsp;</strong><strong>(median treatment duration 24 months)</strong></p><p><strong>N=</strong><strong> </strong><strong>2563</strong><strong> </strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Letrozole</strong><strong> (median</strong></p><p><strong>treatment</strong><strong> duration 47 months)</strong></p><p><strong>N=</strong><strong> </strong><strong>2566</strong><strong> </strong></p><p><strong>n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Any</strong><strong> </strong><strong>adverse</strong><strong> </strong><strong>event</strong></p></td><td style="vertical-align:top"><p>2234 (87.2)</p></td><td style="vertical-align:top"><p>2418(94.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>90 (3.5)</p></td><td style="vertical-align:top"><p>135 (5.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>91 (3.6)</p></td><td style="vertical-align:top"><p>138 (5.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal</strong></p></td><td style="vertical-align:top"><p>725 (28.3)</p></td><td style="vertical-align:top"><p>1030 (40.1)</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>290 (11.3)</p></td><td style="vertical-align:top"><p>432 (16.8)</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>221 (8.6)</p></td><td style="vertical-align:top"><p>355 (13.8)</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea (NOS)</p></td><td style="vertical-align:top"><p>128 (5.0)</p></td><td style="vertical-align:top"><p>199 (7.8)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting (NOS)</p></td><td style="vertical-align:top"><p>75 (2.9)</p></td><td style="vertical-align:top"><p>116 (4.5)</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain (NOS)</p></td><td style="vertical-align:top"><p>74 (2.9)</p></td><td style="vertical-align:top"><p>112 (4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>72 (2.8)</p></td><td style="vertical-align:top"><p>122 (4.8)</p></td></tr><tr><td style="vertical-align:top"><p>Flatulence</p></td><td style="vertical-align:top"><p>47 (1.8)</p></td><td style="vertical-align:top"><p>55 (2.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>General</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>1155 (45.1)</p></td><td style="vertical-align:top"><p>1462 (57.0)</p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>862 (33.6)</p></td><td style="vertical-align:top"><p>1139 (44.4)</p></td></tr><tr><td style="vertical-align:top"><p>Edema (NOS)</p></td><td style="vertical-align:top"><p>471 (18.4)</p></td><td style="vertical-align:top"><p>632 (24.6)</p></td></tr><tr><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>59 (2.3)</p></td><td style="vertical-align:top"><p>83 (3.2)</p></td></tr><tr><td style="vertical-align:top"><p>Pain (NOS)</p></td><td style="vertical-align:top"><p>56 (2.2)</p></td><td style="vertical-align:top"><p>68 (2.7)</p></td></tr><tr><td style="vertical-align:top"><p>Edema peripheral</p></td><td style="vertical-align:top"><p>41 (1.6)</p></td><td style="vertical-align:top"><p>59 (2.3)</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>9 (0.4)</p></td><td style="vertical-align:top"><p>51 (2.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections</strong><strong> and Infestations</strong></p></td><td style="vertical-align:top"><p>166 (6.5)</p></td><td style="vertical-align:top"><p>251 (9.8)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigation</strong></p></td><td style="vertical-align:top"><p>184 (7.2)</p></td><td style="vertical-align:top"><p>251 (9.8)</p></td></tr><tr><td style="vertical-align:top"><p>Weight increased</p></td><td style="vertical-align:top"><p>55 (2.1)</p></td><td style="vertical-align:top"><p>69 (2.7)</p></td></tr><tr><td style="vertical-align:top"><p>Weight decreased</p></td><td style="vertical-align:top"><p>52 (2.0)</p></td><td style="vertical-align:top"><p>74 (2.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism</strong><strong> and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>551 (21.5)</p></td><td style="vertical-align:top"><p>811 (31.6)</p></td></tr><tr><td style="vertical-align:top"><p>Hypercholesterolaemia</p></td><td style="vertical-align:top"><p>401 (15.6)</p></td><td style="vertical-align:top"><p>582 (22.7)</p></td></tr><tr><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>119 (4.6)</p></td><td style="vertical-align:top"><p>178 (6.9)</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycaemia (NOS)</p></td><td style="vertical-align:top"><p>48 (1.9)</p></td><td style="vertical-align:top"><p>78 (3.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>978 (38.2)</p></td><td style="vertical-align:top"><p>1288 (50.2)</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>565 (22.0)</p></td><td style="vertical-align:top"><p>806 (31.4)</p></td></tr><tr><td style="vertical-align:top"><p>Arthritis (NOS)</p></td><td style="vertical-align:top"><p>173 (6.7)</p></td><td style="vertical-align:top"><p>349 (13.6)</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>171 (6.7)</p></td><td style="vertical-align:top"><p>318 (12.4)</p></td></tr><tr><td style="vertical-align:top"><p>Fractures</p></td><td style="vertical-align:top"><p>152 (5.9)</p></td><td style="vertical-align:top"><p>279 (10.9)</p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>129 (5.0)</p></td><td style="vertical-align:top"><p>162 (6.3)</p></td></tr><tr><td style="vertical-align:top"><p>Bone pain</p></td><td style="vertical-align:top"><p>70 (2.7)</p></td><td style="vertical-align:top"><p>157 (6.1)</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Letrozole</strong><strong> &nbsp;(median</strong></p><p><strong>treatment</strong><strong> duration 24 months)</strong></p><p><strong>N=</strong><strong> </strong><strong>2563</strong><strong> </strong><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Letrozole</strong><strong> (median</strong></p><p><strong>treatment</strong><strong> duration 47 months)</strong></p><p><strong>N=</strong><strong> </strong><strong>2566</strong><strong> </strong><strong>n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>70 (2.7)</p></td><td style="vertical-align:top"><p>90 (3.5)</p></td></tr><tr><td style="vertical-align:top"><p>Muscle cramp</p></td><td style="vertical-align:top"><p>39 (1.5)</p></td><td style="vertical-align:top"><p>52 (2.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Neoplasms</strong><strong> </strong><strong>benign,</strong><strong> </strong><strong>malignant</strong><strong> </strong><strong>and</strong><strong> unspecified</strong></p></td><td style="vertical-align:top"><p>51 (2.0)</p></td><td style="vertical-align:top"><p>83 (3.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous</strong><strong> </strong><strong>system</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>865 (33.7)</p></td><td style="vertical-align:top"><p>1200 (46.8)</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>516 (20.1)</p></td><td style="vertical-align:top"><p>792 (30.9)</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>363 (14.2)</p></td><td style="vertical-align:top"><p>547 (21.3)</p></td></tr><tr><td style="vertical-align:top"><p>Sensory disturbance (NOS)</p></td><td style="vertical-align:top"><p>41 (1.6)</p></td><td style="vertical-align:top"><p>65 (2.5)</p></td></tr><tr><td style="vertical-align:top"><p>Hypoaesthesia</p></td><td style="vertical-align:top"><p>41 (1.6)</p></td><td style="vertical-align:top"><p>60 (2.3)</p></td></tr><tr><td style="vertical-align:top"><p>Memory impairment</p></td><td style="vertical-align:top"><p>35 (1.4)</p></td><td style="vertical-align:top"><p>52 (2.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>320 (12.5)</p></td><td style="vertical-align:top"><p>425 (16.6)</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>149 (5.8)</p></td><td style="vertical-align:top"><p>204 (8.0)</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>115 (4.5)</p></td><td style="vertical-align:top"><p>158 (6.2)</p></td></tr><tr><td style="vertical-align:top"><p>Anxiety</p></td><td style="vertical-align:top"><p>78 (3.0)</p></td><td style="vertical-align:top"><p>103 (4.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>130 (5.1)</p></td><td style="vertical-align:top"><p>172 (6.7)</p></td></tr><tr><td style="vertical-align:top"><p>Pollakiuria</p></td><td style="vertical-align:top"><p>47 (1.8)</p></td><td style="vertical-align:top"><p>65 (2.5)</p></td></tr><tr><td style="vertical-align:top"><p>Incontinence (NOS)</p></td><td style="vertical-align:top"><p>45 (1.8)</p></td><td style="vertical-align:top"><p>56 (2.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>303 (11.8)</p></td><td style="vertical-align:top"><p>412 (16.1)</p></td></tr><tr><td style="vertical-align:top"><p>Vulvovaginal dryness</p></td><td style="vertical-align:top"><p>137 (5.3)</p></td><td style="vertical-align:top"><p>184 (7.2)</p></td></tr><tr><td style="vertical-align:top"><p>Vaginal haemorrhage</p></td><td style="vertical-align:top"><p>123 (4.8)</p></td><td style="vertical-align:top"><p>157 (6.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory</strong><strong> </strong><strong>Disorders</strong></p></td><td style="vertical-align:top"><p>280 (10.9)</p></td><td style="vertical-align:top"><p>396 (15.4)</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>140 (5.5)</p></td><td style="vertical-align:top"><p>208 (8.1)</p></td></tr><tr><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>96 (3.7)</p></td><td style="vertical-align:top"><p>141 (5.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>830 (32.4)</p></td><td style="vertical-align:top"><p>1117 (43.5)</p></td></tr><tr><td style="vertical-align:top"><p>Sweating increased</p></td><td style="vertical-align:top"><p>619 (24.2)</p></td><td style="vertical-align:top"><p>867 (33.8)</p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>112 (4.4)</p></td><td style="vertical-align:top"><p>147 (5.7)</p></td></tr><tr><td style="vertical-align:top"><p>Dry skin</p></td><td style="vertical-align:top"><p>42 (1.6)</p></td><td style="vertical-align:top"><p>59 (2.3)</p></td></tr><tr><td style="vertical-align:top"><p>Rash NOS</p></td><td style="vertical-align:top"><p>41 (1.6)</p></td><td style="vertical-align:top"><p>58 (2.3)</p></td></tr><tr><td style="vertical-align:top"><p>Dermatitis exfoliative (NOS)</p></td><td style="vertical-align:top"><p>34 (1.3)</p></td><td style="vertical-align:top"><p>54 (2.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>1376 (53.7)</p></td><td style="vertical-align:top"><p>1662 (64.8)</p></td></tr><tr><td style="vertical-align:top"><p>Flushing (1)</p></td><td style="vertical-align:top"><p>1273 (49.7)</p></td><td style="vertical-align:top"><p>1548 (60.3)</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension (NOS)</p></td><td style="vertical-align:top"><p>122 (4.8)</p></td><td style="vertical-align:top"><p>178 (6.9)</p></td></tr><tr><td style="vertical-align:top"><p>Lymphoedema (NOS)</p></td><td style="vertical-align:top"><p>68 (2.7)</p></td><td style="vertical-align:top"><p>91 (3.5)</p></td></tr></tbody></table><p><strong>&nbsp;</strong>(1) Includes terms &ldquo;hot flashes/hot flushes&rdquo;.</p><p>(NOS) : Not Otherwise Specified</p><p>&nbsp;</p><p>The most frequent adverse events irrespective of drug relationship (cut-off frequency of at least 2%) reported in the 604/2566 (23.5%) patients randomized to the letrozole arm who had actually completed 5 years of treatment were: flushing (384, 64%), asthenia (288, 47.4%), increased sweating (241, 40%), headache (221, 37%), arthralgia (220, 36%), hypercholesterolemia (187, 31%), edema NOS (160, 26.5%) and dizziness (145, 24%).</p><p>In contrast to general self-reported adverse events presented in the table above, dates of onset were recorded for serious adverse events (SAE) and for targeted adverse events of fracture, osteoporosis and cardiovascular events. The comparison between the letrozole randomized arm to placebo until switch is therefore more meaningful for these events.</p><p>&nbsp;</p><p><strong>Osteoporosis and fracture</strong></p><p>After the study unblinding, patients randomized to the placebo arm were offered to switch to letrozole or discontinue treatment.</p><p>The updated results from the MA-17 core safety population obtained after unblinding, showed that at a median follow-up of 49 months, the incidence of osteoporosis any time after randomization was higher in patients originally randomized in the letrozole arm than for patients in the placebo until switch arm [12.3% in letrozole arm vs. 7.4% in placebo until switch arm (<em>P</em>&lt;0.001)].</p><p>The incidence of bone fractures, any time after randomization, was significantly higher in patients who received letrozole than for placebo until switch (10.9% vs. 7.2%, respectively). In the placebo patients who switched to letrozole, newly diagnosed osteoporosis, any time after switching, was reported in 3.6% while fractures were reported in 5.1% any time after switching.</p><p>In the randomized letrozole arm, 1.9% of patients experienced more than one fracture, compared with 1.1% in the placebo until switch group and 1.0% in the letrozole after switch from placebo group. Of the 74/1448 patients&nbsp; who&nbsp; experienced a&nbsp; fracture&nbsp; after&nbsp; switching&nbsp; to letrozole from placebo, 12 patients had previously experienced a fracture on placebo (and 3 of these patients had experienced more than one fracture on placebo).</p><p>The interpretation of the updated results in the core study is confounded by the fact that after study unblinding, 56% of patients randomized placebo opted to switch to letrozole, resulting in different median exposure to treatment (47 months for letrozole, 28 months for placebo until switch and 20 months for letrozole after switch from placebo).</p><p>Updated results (median follow-up was 40 months) from the bone mineral density (BMD) sub- study conducted in a subset of 219 patients (117 on letrozole and 102 on placebo, including 77 placebo/letrozole switchers), demonstrated that, at 2 years, compared to baseline, patients receiving letrozole had a median decrease of 3.8% in hip BMD compared to 2.0% in the placebo until switch group (<em>P</em>=0.018). There were no statistically significant differences&nbsp; in&nbsp; median&nbsp; % changes from baseline in hip BMD at any other measured time-points other than at 2 years. There were no statistically significant changes in lumbar spine BMD at any time between letrozole and placebo until switch groups. In the 77 placebo patients who switched to letrozole, BMD in the hip and lumbar spine showed a median decrease from baseline of approximately 1-2% at each of the first, second and third annual visits after switching to letrozole. The treatment duration in each group was median 38 months for letrozole, 22 months for placebo until switch and 22 months for letrozole after switch from placebo respectively. (See also <strong>WARNINGS AND PRECAUTIONS, Musculoskeletal </strong>and <strong>Special Populations - Geriatrics </strong>sections<strong>)</strong>.</p><p>&nbsp;</p><p><strong>Cardiovascular events</strong></p><p>As reported in Table 4 below, at a median follow-up of 49 months, the incidence of cardiovascular events any time after randomization was 11.1% for letrozole versus 8.6% for placebo until switch. This is higher than the incidence reported at 28 months follow-up (6.8% in the letrozole arm compared with 6.5% in the placebo arm, see also <strong>WARNINGS AND PRECAUTIONS, Cardiovascular </strong>section<strong>)</strong>.</p><p>&nbsp;</p><p><strong>Table 4 - Cardiovascular disease any time after randomization in the MA-17 study (safety population), median follow-up of 49 months</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top" colspan="2"><p><strong>Letrozole</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong><strong> &nbsp;until switch (1)</strong></p></td><td style="vertical-align:top"><p><strong>Letrozole</strong><strong> &nbsp;after switch (</strong><strong>2)</strong></p></td></tr><tr><td style="vertical-align:top" colspan="2"><p style="text-align:right"><strong>N=2566</strong></p><p style="text-align:right"><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>N=2577</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>N=1448</strong></p><p><strong>n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiovascular</strong><strong> </strong><strong>disease</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>No</p></td><td style="vertical-align:top"><p>2280 (88.9)</p></td><td style="vertical-align:top"><p>2355 (91.4)</p></td><td style="vertical-align:top"><p>1392 (96.1)</p></td></tr><tr><td style="vertical-align:top"><p>Yes</p></td><td style="vertical-align:top"><p>286 (11.1)</p></td><td style="vertical-align:top"><p>222 (8.6)</p></td><td style="vertical-align:top"><p>56 (3.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Type of cardiovascular disease</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Angina requiring CABG</p></td><td style="vertical-align:top"><p>12 (0.5)</p></td><td style="vertical-align:top"><p>13 (0.5)</p></td><td style="vertical-align:top"><p>2 (0.1)</p></td></tr><tr><td style="vertical-align:top"><p>Myocardial Infarction</p></td><td style="vertical-align:top"><p>34 (1.3)</p></td><td style="vertical-align:top"><p>24 (0.9)</p></td><td style="vertical-align:top"><p>4 (0.3)</p></td></tr><tr><td style="vertical-align:top"><p>New or worsening angina</p></td><td style="vertical-align:top"><p>44 (1.7)</p></td><td style="vertical-align:top"><p>32 (1.2)</p></td><td style="vertical-align:top"><p>6 (0.4)</p></td></tr><tr><td style="vertical-align:top"><p>Angina requiring PTCA</p></td><td style="vertical-align:top"><p>14 (0.5)</p></td><td style="vertical-align:top"><p>11 (0.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Thromboembolic event</p></td><td style="vertical-align:top"><p>25 (1.0)</p></td><td style="vertical-align:top"><p>16 (0.6)</p></td><td style="vertical-align:top"><p>7 (0.5)</p></td></tr><tr><td style="vertical-align:top"><p>Stroke/transient ischemic attack</p></td><td style="vertical-align:top"><p>43 (1.7)</p></td><td style="vertical-align:top"><p>33 (1.3)</p></td><td style="vertical-align:top"><p>6 (0.4)</p></td></tr><tr><td style="vertical-align:top"><p>Other</p></td><td style="vertical-align:top"><p>179 (7.0)</p></td><td style="vertical-align:top"><p>140 (5.4)</p></td><td style="vertical-align:top"><p>35 (2.4)</p></td></tr><tr><td style="vertical-align:top"><p>Arrhythmia</p></td><td style="vertical-align:top"><p>103 (4.0)</p></td><td style="vertical-align:top"><p>85 (3.3)</p></td><td style="vertical-align:top"><p>16 (1.1)</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac</p></td><td style="vertical-align:top"><p>66 (2.6)</p></td><td style="vertical-align:top"><p>51 (2.0)</p></td><td style="vertical-align:top"><p>11 (0.8)</p></td></tr><tr><td style="vertical-align:top"><p>Vascular</p></td><td style="vertical-align:top"><p>28 (1.1)</p></td><td style="vertical-align:top"><p>21 (0.8)</p></td><td style="vertical-align:top"><p>4 (0.3)</p></td></tr><tr><td style="vertical-align:top"><p>Valvular</p></td><td style="vertical-align:top"><p>9 (0.4)</p></td><td style="vertical-align:top"><p>5 (0.2)</p></td><td style="vertical-align:top"><p>3 (0.2)</p></td></tr><tr><td style="vertical-align:top"><p>CNS/Cerebrovascular</p></td><td style="vertical-align:top"><p>7 (0.3)</p></td><td style="vertical-align:top"><p>3 (0.1)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Other</p></td><td style="vertical-align:top"><p>8 (0.3)</p></td><td style="vertical-align:top"><p>11 (0.4)</p></td><td style="vertical-align:top"><p>7 (0.5)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>(1) After randomization but until switch to letrozole, if switch occurred; if switch did not occur, then until date of last contact.</p><p>(2) After switch until date of last contact.</p><p>The most frequent cause of non-cancer death during study treatment or within 30 days of stopping treatment (regardless of treatment arm) was cardiovascular. (See <strong>Warnings and Precautions, Cardiovascular</strong><strong> </strong>section).</p><p>The incidence of serious adverse events (all grades 1-5) regardless of study drug relationship was 0.5% in the letrozole group, 1.3% in the placebo not switched arm and 0.3% in letrozole after switch arm. Breast cancer related death reported during treatment or within 30 days of stopping treatment occurred in 0.5% of patients in the letrozole arm, 0.8% in the placebo not switched arm and 0.3% in the letrozole after switch arm. Non-breast cancer related death reported during treatment or within 30 days of stopping treatment occurred in 1.7% of patients in the letrozole arm, 2.6% in the placebo not switched arm and 0.5% in the letrozole after switch arm.</p><p>&nbsp;</p><p><strong>Lipids</strong></p><p>Updated results (median follow-up was approximately 50 months) from the lipid sub-study showed no significant differences between the letrozole and placebo groups at any time.</p><p>The MA-17 study is ongoing. The final study results are pending.</p><p>&nbsp;</p><p><strong>Adverse Events in First-Line Therapy</strong></p><p>Overall, 455 post-menopausal patients with locally advanced or metastatic breast cancer were treated with letrozole in a well-controlled clinical trial and the median time of exposure was 11 months. The incidence of adverse experiences was similar for letrozole and tamoxifen. The most frequently reported adverse experiences were bone pain, hot flushes, back pain, nausea, arthralgia and dyspnea. Discontinuations for adverse experiences other than progression &nbsp;of tumour occurred in 10/455&nbsp; (2%)&nbsp; of&nbsp; patients&nbsp; on letrozole and&nbsp; in 15/455 (3%) of&nbsp;patients&nbsp; on tamoxifen.</p><p>Table 5 below shows the frequency of adverse events considered possibly related to trial drug that have been reported with an incidence of more than 2.0% (whether for letrozole or for tamoxifen) in a well-controlled clinical study with letrozole (2.5 mg daily) and tamoxifen (20 mg daily).</p><p>&nbsp;</p><p><strong>Table 5</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse</strong><strong> Event System Organ Class / Preferred term</strong></p></td><td style="vertical-align:top"><p><strong>Letrozole</strong></p><p><strong>N=</strong><strong> </strong><strong>455</strong><strong> </strong><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen</strong></p><p><strong>N=455</strong><strong> </strong><strong>(%)</strong></p></td></tr><tr><td style="vertical-align:top" colspan="3"><p><strong>Gastrointestinal Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>6.6</p></td><td style="vertical-align:top"><p>6.4</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>2.4</p></td><td style="vertical-align:top"><p>1.3</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>1.5</p></td></tr><tr><td style="vertical-align:top" colspan="3"><p><strong>General</strong><strong> Disorders and Administration Site Conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>2.4</p></td></tr><tr><td style="vertical-align:top" colspan="3"><p><strong>Metabolism</strong><strong> and Nutrition Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Appetite Decreased</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>3.3</p></td></tr><tr><td style="vertical-align:top"><p>Appetite Increased</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top" colspan="3"><p><strong>Nervous</strong><strong> System Disorders</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse</strong><strong> Event System Organ Class / Preferred term</strong></p></td><td style="vertical-align:top"><p><strong>Letrozole</strong></p><p><strong>N=</strong><strong> </strong><strong>455</strong><strong> </strong><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen</strong></p><p><strong>N=455</strong><strong> </strong><strong>(%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>2.4</p></td></tr><tr><td style="vertical-align:top" colspan="3"><p><strong>Skin</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Subcutaneous</strong><strong> </strong><strong>Tissue</strong><strong> Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>5.5</p></td><td style="vertical-align:top"><p>3.3</p></td></tr><tr><td style="vertical-align:top"><p>Sweating Increased</p></td><td style="vertical-align:top"><p>2.0</p></td><td style="vertical-align:top"><p>2.9</p></td></tr><tr><td style="vertical-align:top" colspan="3"><p><strong>Vascular</strong><strong> Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hot Flushes</p></td><td style="vertical-align:top"><p>16.7</p></td><td style="vertical-align:top"><p>14.3</p></td></tr><tr><td style="vertical-align:top"><p>Thromboembolic Events</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>1.9</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong><u>Adverse</u></strong><strong><u> </u></strong><strong><u>Events</u></strong><strong><u> </u></strong><strong><u>in</u></strong><strong><u> </u></strong><strong><u>Second-Line</u></strong><strong><u> </u></strong><strong><u>Therapy</u></strong></p><p>Table 6 below shows in decreasing order of frequency the AEs - considered possibly related to trial drug according to the investigator - that have been reported with an incidence of more than 1.0% for letrozole in a controlled clinical trial with letrozole (2.5 mg daily) and megestrol acetate (160 mg daily) for up to 33 months.</p><p>&nbsp;</p><p><strong>Table 6</strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:66.2pt;margin-top:-330.55pt;width:321.4pt;
 height:337.3pt;z-index:1144;mso-position-horizontal-relative:page' filled="f"
 stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellspacing="0" cellpadding="0"><tbody><tr><td><table style="width:100%" cellspacing="0" cellpadding="0"><tbody><tr><td><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse</strong><strong> </strong><strong>Event</strong></p></td><td style="vertical-align:top"><p><strong>Letrozole</strong></p><p><strong>% (N=174)</strong></p></td><td style="vertical-align:top"><p><strong>Megestrol</strong><strong> </strong><strong>Acetate</strong></p><p><strong>% (N=189)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>6.9</p></td><td style="vertical-align:top"><p>4.8</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>6.3</p></td><td style="vertical-align:top"><p>4.2</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral edema</p></td><td style="vertical-align:top"><p>6.3</p></td><td style="vertical-align:top"><p>3.7</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>5.2</p></td><td style="vertical-align:top"><p>6.3</p></td></tr><tr><td style="vertical-align:top"><p>Hot flushes</p></td><td style="vertical-align:top"><p>5.2</p></td><td style="vertical-align:top"><p>3.7</p></td></tr><tr><td style="vertical-align:top"><p>Hair thinning</p></td><td style="vertical-align:top"><p>3.4</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>Rash (1)</p></td><td style="vertical-align:top"><p>3.4</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>2.9</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>2.9</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td style="vertical-align:top"><p>Weight increase</p></td><td style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>8.5</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain (2)</p></td><td style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>Vaginal bleeding</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>3.2</p></td></tr><tr><td style="vertical-align:top"><p>Leukorrhea</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>2.6</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>3.7</p></td></tr><tr><td style="vertical-align:top"><p>Increased appetite</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>3.7</p></td></tr><tr><td style="vertical-align:top"><p>Increased sweating</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>2.1</p></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table><p>(1) Including: erythematous rash, maculopapular rash.</p><p>(2) Including: arm pain, back pain, leg pain, skeletal pain.</p><p>There were no differences in the incidence and severity of adverse reactions in patients &le; 55 years, 55-69 years and &ge;70 years.</p><p>&nbsp;</p><p><strong><u>Post-Market Adverse Drug Reactions</u></strong></p><p>Spontaneously reported adverse drug reactions are presented below. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or clearly establish a causal relationship to letrozole exposure.</p><p>&nbsp;</p><p><strong>Blood and lymphatic system&nbsp;disorders:</strong></p><p>Leukopenia</p><p><strong>Cardiac</strong><strong> </strong><strong>disorders:</strong></p><p>Palpitations, tachycardia, atrial fibrillation, atrial flutter, cardiac failure</p><p><strong>Eye disorders:</strong></p><p>Cataract, eye irritation, blurred vision</p><p><strong>Gastrointestinal disorders:</strong></p><p>Dyspepsia, abdominal pain, stomatitis, dry mouth</p><p>&nbsp;</p><p><strong>General disorders and&nbsp;administration site conditions:</strong></p><p>Pyrexia, mucosal dryness, thirst</p><p><strong>Hepato-biliary</strong><strong> disorders:&nbsp;</strong></p><p>Increased hepatic enzymes, hepatitis</p><p><strong>Immune</strong><strong> system disorders:&nbsp;</strong></p><p>Anaphylactic reaction</p><p><strong>Infections</strong><strong> and infestations:</strong></p><p>Urinary tract infection</p><p><strong>Investigations:</strong></p><p>Weight increase, weight loss, increase in aminotransferases</p><p><strong>Musculoskeletal and&nbsp;connective tissue disorders:</strong></p><p>Myalgia, osteoporosis, bone fractures</p><p><strong>Neoplasms benign, malignant&nbsp;and unspecified (incl. cysts and polyps):</strong></p><p>Tumour pain</p><p><strong>Nervous<strong> </strong>system</strong><strong> </strong><strong>disorders:</strong></p><p>Memory impairment, dysesthesia (1) , taste disturbance, cerebrovascular accident</p><p><strong>Psychiatric disorders:</strong></p><p>Anxiety (2)</p><p><strong>Renal</strong><strong> </strong><strong>and</strong><strong> urinary disorders:</strong></p><p>Increased urinary frequency</p><p><strong>Reproductive system and&nbsp;breast disorders:</strong></p><p>Vaginal discharge</p><p><strong>Respiratory,</strong><strong> </strong><strong>thoracic and&nbsp;mediastinal</strong><strong> </strong><strong>disorders:</strong></p><p>Cough</p><p><strong>Skin and subcutaneous tissue&nbsp;disorders:</strong></p><p>Rash (3), pruritis, dry skin, urticaria, angioedema, erythema&nbsp;multiforme, toxic epidermal necrolysis</p><p><strong>Vascular disorders:</strong></p><p>Thrombophlebitis (4) , hypertension, pulmonary embolism, arterial thrombosis, cerebrovascular infarction, ischemic cardiac events</p><p>&nbsp;</p><p>(1) Including paresthesia, hypoesthesia</p><p>(2) Including nervousness, irritability</p><p>(3) Including erythematous, maculopapular, psoriaform and vesicular rash</p><p>(4) Including superficial and deep thrombophlebitis</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Isolated cases of letrozole overdose have been reported. In these instances, the highest single dose ingested was 62.5 mg or 25 tablets. While no serious adverse events were reported in these cases, because of the limited data available, no firm recommendations for treatment can be made. In single dose studies the highest dose used was 30 mg, which was well tolerated; in multiple dose trials, the largest dose of 10 mg was well tolerated.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.</p></td></tr></tbody></table><p>&nbsp;</p><p>In general, treatment of overdose with letrozole should be supportive and symptomatic. Vital signs should be monitored in all patients. Complete blood count (CBC) and liver function tests should be monitored in symptomatic patients. Fluid and electrolyte status should be monitored in patients with significant vomiting and/or diarrhea. Administration of activated charcoal may be appropriate in some cases.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Letrozole exerts its antitumour effect by depriving estrogen-dependent breast cancer cells of one of their growth stimuli. In postmenopausal women, estrogens are derived mainly from the action of the aromatase enzyme, which converts adrenal androgens - primarily androstenedione and testosterone - to estrone (E1) and estradiol (E2). The suppression of estrogen biosynthesis in peripheral tissues and the malignant tissue can be achieved by specifically inhibiting the aromatase enzyme.</p><p>In healthy postmenopausal women, single oral doses of 0.1, 0.5 and 2.5 mg letrozole suppressed serum estrone by 75-78% and estradiol by 78% from baseline. Maximum suppression is achieved in 48-78 hours.</p><p>In postmenopausal women with advanced breast cancer, daily letrozole doses of 0.1 to 5 mg suppress estradiol, estrone and estrone sulphate plasma levels by 75 - 95% from baseline in all patients treated. With 0.5 mg doses and higher, many plasma levels of estrone and estrone sulphate are below the limit of detection of the assays, indicating that higher estrogen suppression is achieved with these doses. Estrogen suppression was maintained throughout treatment in all patients.</p><p>Letrozole is highly specific in inhibiting aromatase activity. Impairment of adrenal steroidogenesis has not been observed. No clinically relevant changes in the plasma levels of cortisol, aldosterone, 11-deoxycortisol, 17-hydroxy-progesterone, ACTH (adrenocorticotropic&nbsp; hormone) or in plasma renin activity were found in postmenopausal patients treated with 0.1 to 5 mg letrozole daily. The ACTH stimulation test performed after 6 and 12 weeks of treatment with daily doses of 0.1 to 5 mg letrozole did not indicate any attenuation of aldosterone or cortisol production. Thus, glucocorticoid or mineralocorticoid supplementation is not required.</p><p>Letrozole had no effect on plasma androgen concentrations (androstenedione and testosterone) among healthy postmenopausal women after single doses of 0.1, 0.5 and 2.5 mg, or on plasma androstenedione concentrations among postmenopausal patients treated with daily doses of 0.1 to 5 mg. These results indicate that accumulation of androgenic precursors does not occur. Plasma levels of LH and FSH are not affected by letrozole in patients, nor is thyroid function as evaluated by TSH, T4&nbsp;and T3&nbsp;uptake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption:</strong><strong> </strong>Letrozole is rapidly and completely absorbed from the gastrointestinal tract (absolute bioavailability = 99.9%). Food slightly decreases the rate of absorption (median tmax 1 hour fasted vs. 2 hours fed and mean Cmax 129&plusmn;20.3 nmol/L fasted vs. 98.7&plusmn;18.6 nmol/L fed), but the extent of absorption (area under the curve (AUC)) remains unchanged. This minor effect on absorption rate is not considered to be of clinical relevance and therefore letrozole may be taken with or without food.</p><p>&nbsp;</p><p><strong>Distribution:</strong><strong> </strong>Letrozole is rapidly and extensively distributed into tissues (VdSS&nbsp;= 1.87 &plusmn; 1.47&nbsp; L/kg). Plasma protein binding is approximately 60%, mainly to albumin. The letrozole concentration in erythrocytes is about 80% of that in plasma. After administration of 2.5 mg 14C- labelled letrozole, approximately 82% of the radioactivity in plasma was unchanged compound. Systemic exposure to metabolites is therefore low.</p><p>&nbsp;</p><p><strong>Metabolism: </strong>Metabolic clearance to a pharmacologically inactive carbinol metabolite, CGP 44645, is the major elimination pathway of letrozole (Clm&nbsp;= 2.1 L/h), but it is relatively slow when compared to hepatic blood flow (about 90 L/h). The cytochrome P450 isoenzymes 3A4 and 2A6 were found to be capable of converting letrozole to this metabolite. Formation of minor unidentified metabolites and direct renal and fecal excretion play only a minor role in the overall elimination of letrozole.</p><p>&nbsp;</p><p>Within 2 weeks after administration of 2.5 mg 14C-labelled letrozole to healthy postmenopausal volunteers, 88.2 &plusmn; 7.6% of the radioactivity was recovered in urine and 3.8 &plusmn; 0.9% in feces. At least 75% of the radioactivity recovered in urine up to 216 hours (84.7 &plusmn; 7.8% of the dose) was attributed to the glucuronide of the carbinol metabolite, about 9% to two unidentified metabolites, and 6% to unchanged letrozole.</p><p>&nbsp;</p><p><strong>Excretion: </strong>The apparent terminal elimination half-life in plasma is about 2 days. After daily administration of 2.5 mg steady-state levels are reached within 2 to 6 weeks. Plasma concentrations at steady-state are approximately 7 times higher than concentrations measured after a single dose of 2.5 mg, while they are 1.5 to 2 times higher than steady-state values predicted from the concentrations measured after a single dose, indicating a slight non-linearity in the pharmacokinetics of letrozole upon daily administration of 2.5 mg. Since steady state levels are maintained over time, it can be concluded that no continuous accumulation of letrozole occurs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong>In a variety of preclinical safety studies conducted in standard animal species, there was no evidence of systemic or target organ toxicity.</p><p>Letrozole showed a low degree of acute toxicity in rodents exposed up to 2000 mg/kg. &nbsp;In dogs, letrozole caused signs of moderate toxicity at 100 mg/kg (see Table 13).</p><p>In repeated dose toxicity studies of up to 12 months duration in rats treated with 0.3, 3 and 30 mg/kg and dogs treated with 0.03, 0.3 and 3 mg/kg, the main findings can be attributed to the pharmacological action of the compound. Effects on the liver (increased weight, hepatocellular hypertrophy, fatty changes) were observed, mainly at the high dose level. The no-adverse effect level was 0.3 mg/kg in both species (see Table 14). Increased incidences of hepatic vacuolation (both sexes, high dose) and necrosis (intermediate and high dose females) were also noted in rats treated for 104 weeks in a carcinogenicity study. They may have been associated with the endocrine effects and hepatic enzyme-inducing properties of letrozole. However, a direct drug effect cannot be ruled out.</p><p>&nbsp;</p><p><strong>Table 13 - Acute Toxicity</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Species</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong><strong> </strong><strong>mg/kg</strong></p></td><td style="vertical-align:top"><p><strong>Route</strong></p></td><td style="vertical-align:top"><p><strong>Findings</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mouse</p></td><td style="vertical-align:top"><p>200, 2000</p></td><td style="vertical-align:top"><p>p.o.</p></td><td style="vertical-align:top"><p>LD50: &gt;2000 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Rat</p></td><td style="vertical-align:top"><p>2000</p></td><td style="vertical-align:top"><p>p.o.</p></td><td style="vertical-align:top"><p>LD50: &gt;2000 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Dog</p></td><td style="vertical-align:top"><p>100, 200</p></td><td style="vertical-align:top"><p>p.o.</p></td><td style="vertical-align:top"><p>100 mg/kg: signs of general toxicity; 12 days after dosing: asymptomatic. 200 mg/kg: death within 48 hours</p></td></tr><tr><td style="vertical-align:top"><p>Rat</p></td><td style="vertical-align:top"><p>50, 500</p></td><td style="vertical-align:top"><p>i.p.</p></td><td style="vertical-align:top"><p>LD50: &gt;500 mg/kg</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table</strong><strong> 14 - Long-Term Toxicity</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Duration</strong><strong> </strong><strong>of</strong></p><p><strong>dosing</strong></p></td><td style="vertical-align:top"><p><strong>Species</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong><strong> </strong><strong>(mg/kg)</strong></p><p><strong>/Route</strong></p></td><td style="vertical-align:top"><p><strong>Main</strong><strong> </strong><strong>findings</strong></p></td></tr><tr><td style="vertical-align:top"><p>13 weeks</p></td><td style="vertical-align:top"><p>Mouse</p></td><td style="vertical-align:top"><p>0.6, 6, 60 /p.o.</p></td><td style="vertical-align:top"><p>Pharmacological effects on reproductive tract. 60 mg/kg: &uarr; Liver weight</p></td></tr><tr><td style="vertical-align:top"><p>28 days (pilot)</p></td><td style="vertical-align:top"><p>Rat</p></td><td style="vertical-align:top"><p>0.5, 5, 50 /p.o.</p></td><td style="vertical-align:top"><p>Pharmacological effects on reproductive tract. 50 mg/kg: &uarr; Liver weight</p></td></tr><tr><td style="vertical-align:top"><p>3 months</p></td><td style="vertical-align:top"><p>Rat</p></td><td style="vertical-align:top"><p>0.3, 3, 30 /p.o.</p></td><td style="vertical-align:top"><p>Pharmacological effects on reproductive tract. 3 and 30 mg/kg: &uarr; Liver weight 30 mg/kg: Signs of thyroid activation. <strong>No-adverse effect level: 0.3 mg/kg.</strong></p></td></tr><tr><td style="vertical-align:top"><p>6/12 months</p></td><td style="vertical-align:top"><p>Rat</p></td><td style="vertical-align:top"><p>0.3, 3, 30 /p.o.</p></td><td style="vertical-align:top"><p>Pharmacological effects on reproductive tract. 30 mg/kg: Fractures of long bones (5/40 f); liver weight &uarr; (m). <strong>No-adverse effect level: 0.3 mg/kg.</strong></p></td></tr><tr><td style="vertical-align:top"><p>28 days (pilot)</p></td><td style="vertical-align:top"><p>Dog</p></td><td style="vertical-align:top"><p>5 /p.o.</p></td><td style="vertical-align:top"><p>Pharmacological effects on reproductive tract.</p></td></tr><tr><td style="vertical-align:top"><p>3 months</p></td><td style="vertical-align:top"><p>Dog</p></td><td style="vertical-align:top"><p>0.03, 0.3, 3.0 /p.o.</p></td><td style="vertical-align:top"><p>Pharmacological effects on reproductive tract. Hypertrophy Leydig cells, impaired spermatogenesis at 0.03 mg/kg.</p></td></tr><tr><td style="vertical-align:top"><p>6/12 months</p></td><td style="vertical-align:top"><p>Dog</p></td><td style="vertical-align:top"><p>0.03, 0.3, 3.0 /p.o.</p></td><td style="vertical-align:top"><p>Pharmacological effects on reproductive tract. 3 mg/kg: Centrilobular hypertrophy of liver cells (f). <strong>No-adverse effect level: 0.3 mg/kg</strong></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Letrozole was evaluated for maternal toxicity as well as embryotoxic, fetotoxic and teratogenic potential in female rats following oral administration of daily doses of 0.003, 0.01 or 0.03 mg/kg on gestation days 6 through 17. Oral administration of letrozole to pregnant rats resulted in teratogenicity and maternal toxicity at 0.03 mg/kg. Embryotoxicity and fetotoxicity were seen at doses &ge;0.003 mg/kg and there was an increase in the incidence of fetal malformation among the animals treated. However it is not known whether this was an indirect consequence of the pharmacological activity of letrozole (inhibition of estrogen biosynthesis) or a direct drug effect.</p><p>Two 104-week carcinogenicity studies have been conducted. In one study, rats were treated with letrozole, administered orally, in doses of 0.1, 1.0 and 10 mg/kg/day; in the second study, mice were treated with letrozole orally at doses of 0.6, 6 and 60 mg/kg/day. No treatment related tumours were noted in male animals. In female animals, treatment-related changes in genital tract tumours (a reduced incidence of benign and malignant mammary tumours at all doses in rats and an increased incidence of benign ovarian stromal tumours in mice) were secondary to the pharmacological effect of the compound. In the mouse carcinogenicity study, dermal and systemic inflammation were also noted, particularly in the high dose group, leading to increased mortality at this dose level. It is not known whether these findings were an indirect consequence of the pharmacological activity of letrozole (i.e. linked to long-term estrogen deprivation) or a direct drug effect.</p><p>&nbsp;</p><p><strong>Table 15 - Mutagenicity Studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Study</strong></p></td><td style="vertical-align:top"><p><strong>Test</strong><strong> </strong><strong>System(s)</strong></p></td><td style="vertical-align:top"><p><strong>Strain(s)/</strong></p><p><strong>Target</strong><strong> cells</strong></p></td><td style="vertical-align:top"><p><strong>Concentration</strong><strong> </strong><strong>/ Dose</strong></p></td><td style="vertical-align:top"><p><strong>Observations</strong></p></td></tr><tr><td style="vertical-align:top" colspan="5"><p><strong><em>in</em></strong><strong><em> </em></strong><strong><em>vitro</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Ames</p></td><td style="vertical-align:top"><p>Salmonella typhimurium</p></td><td style="vertical-align:top"><p>TA 98, 100,</p><p>1535, 1537</p></td><td style="vertical-align:top"><p>313-5000 &micro;g/plate*</p></td><td style="vertical-align:top"><p>No evidence of mutagenicity</p></td></tr><tr><td style="vertical-align:top"><p>gene mutation</p></td><td style="vertical-align:top"><p>Chinese Hamster cells</p></td><td style="vertical-align:top"><p>V 79 cells</p></td><td style="vertical-align:top"><p>60-1800 &micro;g/mL*</p></td><td style="vertical-align:top"><p>No evidence of mutagenicity</p></td></tr><tr><td style="vertical-align:top"><p>chromosome aberration</p></td><td style="vertical-align:top"><p>Chinese Hamster cells</p></td><td style="vertical-align:top"><p>Ovary cell line CCL 61</p></td><td style="vertical-align:top"><p>Chromosome study: 50/800 &micro;g/mL* Cytogenetic test: 145-</p><p>1160 &micro;g/mL*</p></td><td style="vertical-align:top"><p>No mutagenic or clastogenic effects</p></td></tr><tr><td style="vertical-align:top" colspan="5"><p><strong><em>in</em></strong><strong><em> </em></strong><strong><em>vivo</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Micronucleus</p></td><td style="vertical-align:top"><p>Rat</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>40, 80, 160 mg/kg / p.o.</p></td><td style="vertical-align:top"><p>No clastogenic or aneugenic effects</p></td></tr></tbody></table><p><strong>&nbsp;</strong>* With or without metabolic activation by a fraction of rat liver microsomes (S-9 mix)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In addition to the active ingredient, letrozole, each tablet also contains the non-medicinal ingredients cellulose compounds (hydroxypropyl cellulose, microcrystalline cellulose and hydroxypropyl methylcellulose), iron oxide yellow, lactose, magnesium stearate, polyethylene glycol, sodium starch glycolate and titanium dioxide..</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Protect from heat and moisture, store at room temperature 15 to 30 &ordm;C (59-86&ordm;F). Keep out of reach and sight of children and pets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Primary packaging: </strong>blister of 30 tablets.</p><p><strong>Secondary packaging: </strong>carton</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Last revised 03/2016.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>